

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Effect of Vitamin D on ventricular remodeling in Heart Failure: A Meta-analysis of Randomized Controlled Trials.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020545
Article Type:	Research
Date Submitted by the Author:	17-Nov-2017
Complete List of Authors:	<p>zhao, jindong; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China,</p> <p>Jia, JingJing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Dong, PingShuan; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhao, Di; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Yang, XuMing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Li, DaoLin; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhang, HuiFeng; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice, Cardiovascular medicine
Keywords:	Meta-analysis, Vitamin D, ventricular remodeling, cardiac function, Heart failure < CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7 **Effect of Vitamin D on ventricular remodeling in Heart Failure: A Meta-analysis of Randomized Controlled Trials**
8
9

10
11
12 **Running title:** Vitamin D treatment of Heart Failure
13

14
15
16
17 **Jin-Dong Zhao, Jing-Jing Jia, Ping-Shuan Dong^{*}, Di Zhao, Xu-Ming Yang, Lai-Jing Du, Hui-Feng Zhang**
18

19
20
21 **Author:** Jin-Dong Zhao, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology,
22

23
24 Luoyang 471003, China. Tel: 18437919892;
25

26
27 E-mail: zhaojindong123@outlook.com
28

29
30
31 ***Corresponding author:** Ping-Shuan Dong, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and
32

33
34 Technology, Luoyang 471003, China. E-mail: pingshuandong@foxmail.com
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7 **Address of all author:** The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology,
8
9 Luoyang 471003, China.

10
11
12
13 **Abstract:** 274

14
15
16
17
18 **Main text:** 2401

19
20
21
22
23 **ABSTRACT:**

24
25 **Objectives:** The level of vitamin D is considered to be associated with the development and progress of heart failure. However, it is still unclear
26
27 that whether supplementation of vitamin D could improve the ventricular remodeling of the patients with heart failure. This study aimed to
28
29 systematically evaluate the influence of additional supplementation of vitamin D on ventricular remodeling of the patients with heart failure as
30
31 well as its safety.
32
33

34
35 **Design:** This study is A Meta-analysis of Randomized Controlled Trials.
36
37
38
39

1
2
3
4
5
6
7 **Setting:** Make a retrieval of PubMed, EMBase, CNKI, Cochrane library and WEB SCINENCE was performed for randomized controlled trials
8
9 (RCTs) pertinent to the effect of vitamin D on ventricular remodeling of the patients with heart failure (all from database creation to October
10
11 2017). RevMan5.3 software was employed for data analysis.

12
13
14 **Participants:** Eventually seven RCTs with a total of 465 patients including 235 cases in Vitamin D group and 230 cases in the control group
15
16 were included.

17
18
19 **Primary and Secondary outcome measures:** LVEDD; LVEF, the incidence of adverse reactions.

20
21 **Results:** Compared with the control group, a significant decrease was observed in vitamin D group in LVEDD (mean difference [MD]
22
23 =-2.31mm, 95% confidence interval [CI]: -4.15- -0.47, P =0.01), and a increase was indicated in LVEF (MD=4.18%, 95% CI: 0.36-7.99, P
24
25 =0.03) has remarkable increase. Subgroup analysis also revealed a remarkably lowered LVEDD in adults (>18 years) and adolescents (<18 years)
26
27 of vitamin D group in relative to the control group. High-dose vitamin D (>4000IU/day) was more effective at reducing LVEDD than low-dose
28
29 (<4000IU/day).

30
31
32
33
34 **Conclusion:** Vitamin D supplementation can inhibit the ventricular remodeling, and improve the cardiac function in patients with heart failure.
35
36
37
38
39

1
2
3
4
5
6
7 **Trial registration:** PROSPERO CRD42017073893
8

9
10
11 **Keywords:** Vitamin D, ventricular remodeling, cardiac function, heart failure
12

13
14 **Strengths and limitations of this study**
15

16
17 ➤ The results of this systematic review and meta-analysis will be highly dependent on the quality of the included primary research studies.
18

19 Only RCTs were adopted in this study.
20

21
22 ➤ Subgroup analysis were performed according to clinical heterogeneity analysis of the included studies.
23

24
25 ➤ This will be the first review to systematically examine the impact of supplementation of vitamin D to the ventricular remodeling of the
26 patients with heart failure. Result will help to guiding clinical medication.
27

28
29 ➤ The results need to be interpreted with caution as there was a few study in the subgroup.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Introduction

Heart failure(HF) is the main factor leading to economic loss due to its characterized by bad prognosis and high mortality rate [1]. In the USA, there are at least 5,000,000 patients with decreased contractile function, and meanwhile, there is also the same amount of patients with the same disease in Western Europe [2,3]. In recent years, prognosis of heart failure has been improved remarkably, and the survival rate has been improved from 43% to 52% [4] in 5-year survival rate. At present, the main treatment methods for heart failure are still β -receptor blocking agents, ACEI/ARB, and aldosterone receptor antagonist, however, though they could reduce adverse cardiac events and improve prognosis of cardiac function [5], heart failure is still a main cause for global mortality rate. Therefore, there is an urgent need for supplementary treatment methods and strategies at present.

Lack or insufficiency of vitamin D may result in cardiovascular and cerebrovascular diseases [6-10]. Many studies have discovered that [11-14] there is a remarkable relation between lack of vitamin D and progression of HF. Studies showed that patients with heart failure were generally in lack of vitamin D and had bad prognosis, and supplementation of vitamin D could reduce mortality rate of patients with heart failure [15-17].

Several studies showed Vitamin D acts as a negative regulator of renin-angiotensin-aldosterone system (RAAS) [18-20], and modulates

1
2
3
4
5
6
7 myocardial extracellular matrix turnovers. Consistently, Vitamin D receptor(VDR) knockout mice show increased RAAS activity, leading to
8
9 hypertension, cardiac hypertrophy, increased water intake and sodium retention [18], and VDR knockout mice show increased metalloprotease
10
11 (MMP) activity, which promotes the destruction of myocardial tissue leading to ventricular remodelling [21,22]. Therefore, lack of vitamin D
12
13 could result in deterioration of HF, and accelerate the myocardial remodeling.
14
15
16
17

18 At present, concerning the influence of vitamin D on ventricular remodeling of patients with heart failure, different studies have controversial
19
20 conclusions. Therefore, this study makes a meta-analysis of influence of vitamin D on ventricular remodeling of patients with heart failure, so as
21
22 to further clarify influence of vitamin D on ventricular remodeling of patients with heart failure.
23
24
25

26 **Materials and Methods**

27 **Search strategy**

28
29 PubMed, EMBase, Cochrane Central Register of Controlled Trials, CNKI and WEB of SCINENCE were retrieved. Medical subject headings:
30
31 “heart failure”, “vitamin D”, “ventricular remodeling”, “heart function tests”, “randomized controlled Trials”; Keywords: “cardiac failure”,
32
33 “myocardial failure”, “heart decompensation”, “left ventricular remodeling”, “ventricular remodelings”, “ventricular myocardial remodeling”,
34
35
36
37
38
39

1
2
3
4
5
6
7 “cholecalciferol”, “vitamin D3”, “controlled clinical trials”. Time frame for the retrieval: establishment of the database to October 1, 2017. The
8
9 reference lists of identified articles were also reviewed.
10
11
12
13

14 **Study selection**

15
16 Inclusion criteria: 1) Randomized controlled trials (RCTs) involving with the effect of Vitamin D on the Ventricular Remodeling of patients with
17 heart failure, with or without blind method or allocation concealment employed; 2) Parallel or crossover trials; 3) Only the data before the
18 washout period used in a crossover test; 4) Available baseline data and changes in left ventricular end-diastolic dimension(LVEDD), left
19 ventricular ejection fraction(LVEF); 5) heart failure defined as New York Heart Association functional class \geq II, or a left ventricular ejection
20 fraction (LVEF) \leq 40%; 6) Participants of any gender, age or ethnicity; 7) Participants without using or changing any micronutrient except for
21 Vitamin D, 8) A minimum 3 months of therapy was necessary for inclusion in the review to ensure the intervention had sufficient time to
22 produce a better effect. Exclusion criteria: 1) Only the abstract reported for reference; 2) Studies with duplicated data, including same group of
23 patients or for whom there were updated results available; 3) The study have no interest outcomes; 4) Animal test and review; 5) Conference
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7 documents; 6) Non-RCTs, cohort studies, retrospective studies. This study was conducted in accordance with the declaration of Helsinki. This
8
9 study was conducted with approval from the Ethics Committee of Henan University of Science and Technology.
10
11

12 13 14 **Data extraction and quality assessment**

15
16 Data were independently extracted from each study by two authors (JD Zhao and JJ Jia) and entered onto a structured spreadsheet, followed by a
17
18 cross check procedure. Disagreements were resolved by consensus or by a third investigator (P. Dong). The following data were extracted from
19
20 each trial: the first author's surname, year of publication; demographic and methodological data; total number, mean age, gender distribution and
21
22 race of enrolled patients; the using or changing drugs for heart failure; baseline seated LVEDD and LVEF at baseline, when available; number of
23
24 patients randomized assigned to each intervention; duration of therapy; incidence and type of adverse events; number of dropouts or with
25
26 drawls because of adverse events; and change from baseline of seated LVEDD and LVEF. Criteria for RCT bias risk evaluation listed in
27
28 Cochrane Handbook for Systematic Reviewer 5.1.0 were adopted, including: 1) random sequence generation, 2) allocation concealment, 3)
29
30 blinding of patients and personnel, 4) blinding of outcome assessment, 5) incomplete outcome data, 6) selective reporting risk. Then an
31
32 evaluation system with "low risk", "high risk" and "not clear" was established according to the six criteria as describes above [23].
33
34
35
36
37
38
39
40

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Outcome assessed

Primary endpoints: LVEDD; Secondary endpoints: LVEF, the incidence of adverse reactions.

Data analysis and synthesis

RevMan5.3 software was employed for data analysis, with risk ratio (RR) and 95% confidence interval (CI) used for binary variables, mean difference (MD) and 95% CI for continuous variables, as well as a test level $\alpha=0.05$. Following clinical heterogeneity analysis of the included studies, statistical heterogeneity was assessed using χ^2 based Cochran Q statistic and I^2 [24]. For the Q statistic, $P \geq 0.1$ indicates homogeneity among multiple similar studies, and fixed effects model can be employed for Meta analysis; while $P < 0.1$ indicates were considered to indicate statistically significant heterogeneity, analyzed by random-effects model. For the I^2 statistic, $I^2 < 25\%$ indicates low heterogeneity, while $I^2 > 50\%$ indicates moderate to high heterogeneity [25].

Results

Selection and description of studies

157 published papers were collected after the initial screening, and eventually seven RCTs [26-32] with a total of 465 patients including 235 cases in Vitamin D group and 230 cases in the control group were included through reviewing the title, abstract and full text, as well as eliminating duplicate documents, non-randomized controlled trials, and those failed to meet the inclusion criteria. See **Figure 1** for the screening process.

In the seven included studies [26-32], four studies reported a correct random method[27-29,32]; two study adopted allocation concealment[29,32], and six studies used double blind[26-30,32] . See **Figure 2** for evaluation on the methodology of the studies.

Data of the curative effect on the LVEDD were reported in five studies and LVEF in all the included studies, two studies mentioned adverse reactions [26,30]. Dropout or withdrawal from the research was covered in all the included studies. The study characteristics are shown in **Table 1**, and the basic information of the include population in **Table 2**.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Effects of Vitamin D on LVEDD

The changes in LVEDD of the patients were reported in five studies [26-30], which showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 , $P=0.07$, $I^2=55\%$), thus supporting the analysis using the random effect model. Compared with the control group, a significant decrease was observed in Vitamin D group in LVEDD (mean difference [MD] = -2.31mm, 95% confidence interval [CI]: -4.15- -0.47, $P=0.01$) (**Figure 3**).

Effects of Vitamin D on LVEF

The changes in LVEF of the patients were reported in all the seven studies [26-32], which showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 , $P<0.001$, $I^2=88\%$), thus supporting the analysis using the random effect model. Compared with the control group, a significant increase was observed in Vitamin D group in LVEF (MD=4.18%, 95% CI: 0.36-7.99, $P=0.03$) (**Figure 4**).

Subgroup analysis

The analysis based on age stratification revealed that compared with the control group, both of the adults (aged ≥ 18 years) and Non-adults (aged < 18 years) with heart failure in the Vitamin D group showed a decrease in LVEDD (adults: heterogeneity χ^2 , $P = 0.65$, $I^2 = 0\%$; MD = -1.62mm, 95% CI: -2.83- -0.42, $P = 0.008$; Non-adults: MD = -5.51mm, 95% CI, -8.08- -2.94, $P < 0.001$) (**Figure 5**). These results, however, need to be interpreted with caution as there was only one study in the subgroup of Non-adults.

A subgroup analysis was performed according to dosage of Vitamin D. There was the effect of high-dose Vitamin D on reduction of LVEDD (MD = -1.71mm, 95% CI: -2.95- -0.46, $P = 0.007$), but this effect was not seen with low-dose Vitamin D treatment (MD = -3.38mm, 95% CI: -8.23- 1.48, $P = 0.17$). (**Figure 6**).

Publication bias

There was a significant asymmetry of the funnel plot for the effect of Vitamin D on LVEDD, which may be due to publication bias and other causes (**Figure 7**). On the other hand, no publication bias was found for the effect of Vitamin D on LVEF (**Figure 8**).

Adverse event

Two studies [26,30] reported the adverse events. During the follow-up, no significant adverse event was recorded. No data associated with the incidence of adverse events were recorded in the other three studies.

Discussion

At present, as for influence of vitamin D on ventricular remodeling of patients with heart failure, different studies have controversial conclusions. Results of this study show that, compared with the control group, among patients with heart failure, supplementation of vitamin D could reduce LVEDD (MD = -2.31 mm, 95% CI: -4.15- -0.47, P =0.01), and improve LVEF (MD=4.18%, 95% CI: 0.36-7.99, P =0.03). Besides, it has a more clear effect on high-dose Vitamin D (MD=-1.71mm, 95% CI: -2.95- -0.46, P =0.007).

Most of new treatment methods for chronic heart failure are expensive, and have a high requirement for technology [33], and most of them fail to conform to demand for strict Phase III clinical trial. For patients with heart failure, vitamin D is not only cheap but also safe, and they may obtain more benefits from it [34]. Heart failure refers to that cardiac contraction and diastole are affected due to overload of Ca ion in myocardial

1
2
3
4
5
6
7 cells. Lack of vitamin D may intervene with operation of Ca ion in myocardial cells, thus resulting in cardiomyocyte hypertrophy, and
8
9 intra-organizational inflammatory reaction and fibrosis [35,36]. Low vitamin D level could activate the renin-angiotensin system [37], give rise
10
11 to inflammatory reaction [38], and result in endothelium dysfunction [39]. The effects of Vitamin D on CV system are additionally mediated
12
13 through elevated parathyroid hormone (PTH) levels, that is associated with development of left ventricular (LV) hypertrophy in patients with
14
15 elevated PTH levels [40]. Although there are lots of evidences showing that lack of vitamin D could result in bad prognosis of patients with heart
16
17 failure, as for whether supplementation of vitamin D could benefit the patients with heart failure, different studies have controversial
18
19 conclusions.
20
21
22
23
24
25

26 In recent years, there have also been some relative small RCTs, which studied the influence of vitamin D on patients with heart failure. In 2014
27
28 World Heart Failure Conference, Louise et al [41] reported a RCT which made a 6-month study toward 32 patients with heart failure, and the
29
30 result showed that supplementation of vitamin D had no influence on improving LVEF and improving pro-bnp. A recent system assessment [42]
31
32 also showed that supplementation of vitamin D could not improve the LVEF (WMD: 4.11%, 95% CI: -0.91 to 9.12, P =0.11) of the patients
33
34 with heart failure. However, other studies drew the opposite conclusions. In 2015 European Society of Cardiology, Lowry et al[43] reported a
35
36
37
38
39
40

1
2
3
4
5
6
7 12-month RCT, and the result showed that for patients with heart failure, supplementation of vitamin D could improve the ventricular
8 remodeling (LVEDD -4.46 mm; $p=0.047$), and the LVEF showed a rising trend. It was also showed by a non-RCT [44] that supplementation of
9 vitamin D could make EF value before and after the trial increase remarkably. Elidrissy et al [45] summarized 61 cases of children with
10 cardiomyopathy, they thought the evidence available supports that the most likely cause of cardiomyopathy is hypocalcemia, and suggested for
11 prevention maternal supplementation during pregnancy and lactation with up to 2000 units of vitamin D and 400 units for their infants, which
12 was also similar to study result of Shedeed [29].
13
14
15
16
17
18
19
20
21
22
23

24 Since there are disputes among different study results, therefore, we conduct a meta-analysis of relevant RCT studies, so as to further clarify
25 influence of supplementation of vitamin D on ventricular remodeling of patients with heart failure. Result of this study shows that,
26 supplementation of vitamin D could inhibit myocardial remodeling of the patients, and improve the cardiac function.
27
28
29
30
31
32
33

34 Different studies have different results and conclusions, which may be related to different recommended dosages of vitamin; since there is no
35 uniform standard for recommended dosage of vitamin D at present, therefore, there are differences in recommended dosage of vitamin D in
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7 different trials, which may affect the result. However, there hasn't been a report related to adverse effects concerning dosage of vitamin D.

8
9 Meanwhile, it has a great relation with the selected group, for example, study results of Schleithoff et al [28] showed that there were no
10 remarkable changes in LVEF and LVEDD, and the people included in this study were more than those of NYHA 3-4 level, the degree of heart
11 failure was high, and there was a high rate of lost to follow-up visit (37%).
12
13
14
15
16
17
18

19 The data in changes of LVEDD showed high levels of heterogeneity among the results of the studies. Shedeed [29] studied the cause of
20 heterogeneity according to the subgroup analysis. There was a certain difference in metabolism of vitamin D and cardiac recovery capacity
21 between newborns and adults, which might be the cause of heterogeneity.
22
23
24
25
26

27 Limitation of this study is considered to be although all trials included in this study are RCTs, there are still lots of limitations. 1) the quantity of
28 the people included in the study is relative small, and more large-scale trials are still required to study the effect of vitamin D on patients with
29 heart failure; 2) this study has heterogeneity, and through subgroup analysis and sensitivity analysis, it is discovered that, the age stratification of
30 the studied group is the source of heterogeneity; 3) there is difference in recommended dosage of vitamin D in different trials, which may affect
31 the study result, and more trials are required to explore the relationship between dosage and effect.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

In conclusion, this study shows that supplementation of vitamin D could inhibit myocardial remodeling of patients with heart failure, and improve their cardiac function. Therefore, in clinical practices, for patients with heart failure, the treatment applying additional supplementation of vitamin D may bring more benefits to the patients.

Table 1 Study characteristics.

Author	Design	Blinding	Vitamin D Dose	Follow-up Duration	Study population	Primary Outcome
Turrini et al, 2017	Prospective RCT	Double-blind	300.000 IU at Baseline 50.000IU/mo	6 mo	Chronic HF, 25(OH)D <20 ng/mL, 60 y < Age,	6MWD, echocardiography Parameters, hormonal
Witte et al, 2016	Prospective RCT	Double-blind	4000IU/d	12 mo	Chronic HF, NYHA class II–III, LVEF<45%, 25(OH)D <20 ng/mL	6MWD, echocardiography parameters

Qu et al, 2015	Prospective RCT	Single-blind	1000 IU/d	3 mo	NYHA class III-IV	echocardiography parameters, BNP, 25(OH)D
Dalbeni et al, 2014	Prospective RCT	Double-blind	4000IU/d	25 wk	Chronic HF, LVEF<55%, NYHA class>II, 25(OH)D <30ng/mL, Age >40 y,	Echocardiographic parameters, NYHA class, NT-proBNP
Boxer er al,2014	Prospective RCT	Double-blind	50000IU/wk	6mo	Age ≥50 y, NYHA class II-IV, 25(OH)D <37.5 ng/mL	Echocardiographic parameters, serum analysis, urine analysis
Shedeed, 2012	Prospective RCT	Double-blind	1000 IU/d	12 wk	Congestive HF, LVEF<40%, LV>2 SD for age and sex	Echocardiographic parameters
Schleithoff et al, 2006	Prospective RCT	Double-blind	2000 IU/d	9 mo	Chronic HF, NYHA class II-IV	Survival rates, NT-proBNP, Pro-and anti-inflammatory cytokines, Echocardiographic parameters,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

†25(OH)D; ‡6MWD; §HF; **IU; ††LV; ‡‡LVEF; §§NT-proBNP; ***NYHA;

Table 2 Study population characteristics.

Author	Intervention	Number (n)	Age (years)	Male (%)	LVEF (%)	NYHA			LVEDD (mm)	25(OH)D (ng/mL)	Ischemic Hypertension Cause (%)	Diabetes (%)	
						Class II(%)	Class III(%)	Class IV(%)					
Turrini et al, 2017	Vitamin D Placebo	17 16	77±7 79±7	35.3 43.8	54.7±13.8 49.2±19.1	64.7 68.7	35.3 21.3	0 0	51±1.58 54±3.48	9.4±5.2 9.6±7.3	41.2 43.7	64.7 43.7	35.3 18.7
Witte et al, 2016	Vitamin D Placebo	80 83	68.5±12.45 69.0±13.78	83.8 74.7	25.6±10.80 26.5±10.62	92.5 85.5	7.5 14.5	0 0	57.6±8.62 58.0±6.49	38.2±24.81 36.4±20.24	55.0 60.2	NR NR	21.3 24.1

† 25-hydroxyvitamin D
‡ 6-minute walk distance
§ heart failure
** international units
†† left ventricular
‡‡ left ventricular ejection fraction
§§ N-terminal pro-B-type natriuretic peptide
*** New York Heart Association

7	Qu et al,	Vitamin D	22	70±7	59.3	34.9±3.8	NR	NR	NR	NR	NR	NR	66.7	81.5
8														
9	2015	Blank	17	69±8	51.8	34.6±3.9	NR	NR	NR	NR	NR	NR	63.0	85.2
10														
11	Dalbeni et	Vitamin D	13	71.2±6.22	84.6	39.08±8.00	58.8*	50.0**		53.9±6.81	16.2±6.59	76.9	100	NR
12														
13	al, 2014	Placebo	10	73.4±13.78	60.0	43.6±7.63	41.2*	50.0**		50.6±7.04	16.0±6.15	90	100	NR
14														
15	Boxer er	Vitamin D	19	65.8±10.6	48.4	39.2±13.2	55.0	73.0	0	NR	19.1±9.3	25.8	83.0	51.6
16														
17	al, 2014	Placebo	15	66.0±10.4	54.5	36.1±14.5	45.0	27.0	0	NR	17.8±9.0	30.3	84.8	42.4
18														
19	Shedeed,	Vitamin D	42	0.86±1.3	64.29	36.4±2.26	NR	NR	NR	32.81±4.6	13.4±2.21	NR	NR	NR
20														
21	2012	Placebo	38	0.93±1.0	57.89	37.2±2.62	NR	NR	NR	30.7±5.2	14.0±2.46	NR	NR	NR
22														
23		Vitamin D+	42	57±7.41	85.25	32.5±8.67	NR	NR	NR	69.0±8.89	14.4±7.85	47	38	20
24														
25	Schleithoff	Calcium												
26														
27	et al, 2006	Placebo+	51	54±8.89	80.65	33.0±7.56	NR	NR	NR	69.0±9.26	15.3±7.48	40	32	23
28		Calcium												
29														
30														
31														
32														
33														
34														
35														

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

†††NR

For peer review only

††† Not reported
*I and II
** III and IV

Contributor ship statement

Jin-Dong Zhao: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND Drafting the work or revising it critically for important intellectual content; AND Final approval of the version to be published; AND Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Jing-Jing Jia: participated in writing

Ping-Shuan Dong*: served as scientific advisors

Di Zhao: participated in technical editing of the manuscript

Xu-Ming Yang: critically reviewed the study proposal

Dao-Lin Li: collected data

Hui-Feng Zhang: collected data

Disclosure of conflict of interest

1
2
3
4
5
6
7 None.
8
9
10

11 **Funding**

12 This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
13
14
15
16
17
18

19 **Data sharing statement**

20 The authors declare that they willing to share their data directly.
21
22
23
24
25
26

27 **References**

- 28
29 1. Mengchao Jin, Siqi Wei, Rongrong Gao, et al. Predictors of Long-Term Mortality in Patients With Acute Heart Failure. Int Heart J 2017;
30 58: 409-15.
31
32
- 33
34 2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the
35 American Heart Association. Circ Heart Fail 2013; 6 : 606–19.
36
37
38
39

- 1
- 2
- 3
- 4
- 5
- 6
- 7 3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007; 93: 1137–46.
- 8
- 9 4. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004;
- 10 292: 344-50.
- 11
- 12
- 13
- 14 5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The
- 15 Task Force for the Diagnosis of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration
- 16 with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012; 14: 803-69
- 17
- 18
- 19
- 20
- 21 6. Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. *Am J Clin Nutr* 2011; 94:
- 22 534-42
- 23
- 24
- 25
- 26 7. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. *Curr Opin Nephrol Hypertens* 2012; 21: 492–9.
- 27
- 28
- 29 8. Karakas M, Thorand B, Zierer A, et al. Low levels of serum 25-hydroxyvitamin D are associated with increased risk of myocardial
- 30 infarction, especially in women: results from the MONICA/KORA Augsburg case-cohort study. *J Clin Endocrinol Metab* 2013; 98: 272–
- 31 80.
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

- 1
2
3
4
5
6
7 9. Sun Q, Pan A, Hu FB, et al. 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. *Stroke* 2012; 43:
8 1470–7.
9
- 10 10. Desai CK, Huang J, Lokhandwala A, et al. The role of vitamin supplementation in the prevention of cardiovascular disease events. *Clin*
11 *Cardiol* 2014; 37: 576–81
12
- 13 11. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin D—markers for cardiovascular and all cause mortality in heart
14 failure. *Eur J Heart Fail* 2011; 13: 626–32.
15
- 16 12. Liu L, Chen Chen M, Hankins SR, et al. Serum 25-hydroxyvitamin D concentration and mortality from heart failure and cardiovascular
17 disease, and premature mortality from all-cause in United States adults. *Am J Cardiol* 2012; 110: 834–9.
18
- 19 13. Ford JA, MacLennan GS, Avenell A, et al. Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and
20 meta-analysis. *Am J Clin Nutr* 2014; 100: 746–55.
21
- 22 14. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease : a meta-analysis of prospective
23 studies. *Circ Cardiovasc Qual Outcomes* 2012; 5: 819–29.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47


15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guide. *J Clin Endocrinol Metab* 2011; 96: 1911-30.
16. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. *Eur J Heart Fail* 2012; 14: 357–66
17. Pourjabbar A, Dwivedi G, Haddad H. The role of vitamin D in chronic heart failure. *Curr Opin Cardiol*. 2013; 28: 216–22.
18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest* 2002; 110: 229e38.
19. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) Study. *Clin Chim Acta* 2010; 411: 1354e60.
20. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. *Hypertension* 2010; 55: 1283e8.

- 1
2
3
4
5
6
7 21. Weber KT, Weglicki WB, Simpson RU. Macro- and micronutrient dyshomeostasis in the adverse structural remodeling of myocardium.
8
9 Cardiovasc Res 2009; 81: 500e8.
- 10
11 22. Agarwal M, Phan A, Willix Jr R, Barber M, Schwarz ER. Is vitamin D deficiency associated with heart failure? A review of current
12
13 evidence. J Cardiovasc Pharmacol Ther. 2011; 16: 354e63.
- 14
15 23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The
16
17 Cochrane Collaboration, 2011. Available at: www.cochrane-hand-book.org.
- 18
19 24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
- 20
21 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58.
- 22
23 26. Turrini F, Scarlini S, Giovanardi P, et al.
24
25 Effects of cholecalciferol supplementation in patients with stable heart failure and low vitamin D levels (ECSPLOIT-D). A double-blind, ran
26
27 domized, placebo-controlled pilot study. Minerva Cardioangiol 2017 DOI: 10.23736/S0026-4725.17.04340-7
- 28
29 27. Dalbeni A, Scaturro G, Degan M, et al. Effects of six months of vitamin D supplementation in patients with heart failure: a randomized
30
31 double-blind controlled trial. Nutr Metab Cardiovasc Dis 2014; 24: 861–8.
- 32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

- 1
2
3
4
5
6
7 28. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart
8 failure: a double-blind, randomized, placebocontrolled trial. *Am J Clin Nutr* 2006; 83: 754–9.
9
10
11 29. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart failure. *Pediatr Cardiol* 2012; 33: 713–9.
12
13 30. Witte KK, Byrom R, Gierula J, et al. Effects of vitamin D on cardiac function in patients with chronic HF: the VINDICATE study. *J Am*
14
15 *Coll Cardiol* 2016; 67: 2593-603.
16
17 31. Qu Jun, Wang Zhen, Song hong-bo, et al. The Clinical Effect of Vitamin D 3 Supplementation on Cardiac Function in Patients with
18
19 Ischemic Heart Failure. *Chinese and Foreign Medical Research*, 2015, 13: 3-5.
20
21 32. Boxer RS, Hoit BD, Schmotzer BJ, et al. The effect of vitamin D on aldosterone and health status in patients with heart failure. *J Card Fail*
22
23 2014; 20: 334–42
24
25 33. Rie Amao, Teruhiko Imamura, Yasuo Nakahara, et al. Reversible Motor Paralysis and Early Cardiac Rehabilitation in Patients With
26
27 Advanced Heart Failure Receiving Left Ventricular Assist Device Therapy. *Int Heart J* 2016; 57: 766-8
28
29 34. Witte KK, Byrom R. Micronutrients for chronic heart failure: end of the road or path to enlightenment? *J Am Coll Cardio HF* 2014; 2: 318–
30
31 20.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

- 1
2
3
4
5
6
7 35. Weisshaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function II direct and indirect effects. *Am J Physiol* 1987; 253:
8
9 E675–83
10
11
12 36. Chen S, Law CS, Grigsby CL, et al. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy.
13
14 *Circulation* 2011; 124: 1838–47.
15
16
17 37. Vaidya A, Williams JS. The relationship between vitamin D and the renin angiotensin system in the pathophysiology of hypertension,
18
19 kidney disease, and diabetes. *Metabolism* 2012; 61: 450–8.
20
21
22 38. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting
23
24 MAPK phosphatase-1. *J Immunol* 2012; 188: 2127–35.
25
26
27 39. Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial function and dysfunction. *Arch Med Sci* 2012; 8: 4–5.
28
29
30 40. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. *Eur Heart J* 2003; 24: 2054e60.
31
32
33 41. LLLouise Schierbeck, J L Madsen, U C Bang, et al. The effect of vitamin D supplementation in vitamin D deficient men with heart failure.
34 A randomized controlled trial.:P1686. *European journal of heart failure* 2014, 16, 335 Online Publication Date: 2014
35
36
37
38
39

- 1
2
3
4
5
6
7 42. Jiang WL, Gu HB, Zhang YF, et al. Vitamin D Supplementation in the Treatment of Chronic Heart Failure: A Meta-analysis of
8
9 Randomized Controlled Trials. Clin Cardiol 2016;39:56-61.
10
11
12 43. Lowry J , Gierula J , Byrom R, et al. Vitamin D supplementation improves the size and function of the left ventricle in patients with heart
13
14 failure . European heart journal 2015, 36, 665 Online Publication Date: 2016
15
16
17 44. Zia AA, Komolafe BO, Moten M, et al. Supplemental vitamin D and calcium in the management of African Americans with heart failure
18
19 having hypovitaminosis D. Am J Med Sci 2011;341:113-118.
20
21
22 45. Elidrissy AT, MunawarahM, Alharbi KM. Hypocalcemic rachitic cardiomyopathy in infants. J Saudi Heart Assoc 2013; 25: 25-33.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47



33 **Figure 1** Flow diagram of study selection.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Boxer 2014	+	+	?	+	+	+
Dalbeni 2014	+	?	+	+	+	+
Qu 2015	?	?	?	+	+	+
Schleithoff 2006	+	?	?	+	+	+
Shedeed 2012	+	+	+	+	+	+
Turrini 2017	?	?	+	+	+	+
Witte 2016	?	?	+	+	+	+

Figure 2 Quality assessment.




Figure 3 : Forest plot showing the effect of Vitamin D on LVEDD




Figure 4: Forest plot showing the effect of Vitamin D on LVEF




Figure 5: Subgroup analysis of effect of Vitamin D on LVEDD according to patients' age.




Figure 6: Subgroup analysis of effect of Vitamin D on LVEDD according to dose of Vitamin D.




Figure 7: Funnel plots for the effect of Vitamin D on LVEDD

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 8: Funnel plots for the effect of Vitamin D on LVEF.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	23

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Effect of Vitamin D on Ventricular Remodeling in Heart Failure: A Meta-analysis of Randomized Controlled Trials.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020545.R1
Article Type:	Research
Date Submitted by the Author:	08-Mar-2018
Complete List of Authors:	<p>zhao, jindong; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China,</p> <p>Jia, JingJing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Dong, PingShuan; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhao, Di; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Yang, XuMing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Li, DaoLin; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhang, HuiFeng; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice, Cardiovascular medicine
Keywords:	Meta-analysis, Vitamin D, ventricular remodeling, cardiac function, Heart failure < CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Effect of Vitamin D on Ventricular Remodeling in Heart Failure: A**
5
6 **Meta-analysis of Randomized Controlled Trials**
7
8
9

10 **Running title:** Vitamin D treatment of Heart Failure
11

12
13 **Jin-Dong Zhao, Jing-Jing Jia, Ping-Shuan Dong^{*}, Di Zhao, Xu-Ming Yang,**
14
15

16 **Lai-Jing Du, Hui-Feng Zhang**
17
18

19
20 **Author:** Jin-Dong Zhao, Department of Cardiology, The First Affiliated Hospital, and
21

22 College of Clinical Medicine of Henan University of Science and Technology,
23

24
25 Luoyang 471003, China. Tel: 18437919892;
26

27
28 E-mail: zhaojindong123@outlook.com
29
30

31
32
33 ***Corresponding author:** Ping-Shuan Dong, Department of Cardiology, The First
34

35 Affiliated Hospital, and College of Clinical Medicine of Henan University of Science
36

37 and Technology, Luoyang 471003, China. E-mail: pingshuandong@foxmail.com
38
39

40
41
42 **Address of all author:** The First Affiliated Hospital, and College of Clinical
43

44 Medicine of Henan University of Science and Technology, Luoyang 471003, China.
45
46

47
48
49 **Abstract: 291**
50

51
52
53
54 **Main text: 2900**
55
56

ABSTRACT:

Objectives: The level of vitamin D is considered to be associated with the development and progression of heart failure(HF). However, it is still unclear whether supplementation of vitamin D could improve ventricular remodelling in patients with HF. This study aimed to systematically evaluate the influence and safety of additional vitamin D supplementation on ventricular remodelling in patients with HF.

Design: This study is a meta-analysis of randomized controlled trials.

Setting: The PubMed, EMBASE, CNKI, Cochrane library, Web of Science databases and grey literature were searched for randomized controlled trials (RCTs) regarding the effect of vitamin D on ventricular remodelling in patients with HF (from database creation to October 2017). RevMan5.3 software was employed for data analysis.

Participants: Seven RCTs with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included.

Primary and secondary outcome measures: Left ventricular end-diastolic dimension(LVEDD), left ventricular ejection fraction(LVEF), and the incidence of adverse reactions.

Results: Compared with the control group, a decrease in the LVEDD (mean difference [MD] =-2.31mm, 95% confidence interval [CI]: -4.15- -0.47, P =0.01) and an increase in the LVEF (MD=4.18%, 95% CI: 0.36-7.99, P =0.03) were observed in the vitamin D group. Subgroup analysis also revealed a reduced LVEDD in adults

(>18 years) and adolescents (<18 years) of the vitamin D group relative to that in those of the control group. High-dose vitamin D (>4,000IU/day) was more effective at reducing the LVEDD than low-dose vitamin D (<4,000IU/day). Moreover, vitamin D supplementation was more effective at reducing the LVEDD and increasing the LVEF in patients with reduced ejection fraction than in patients without reduced ejection fraction.

Conclusion: Vitamin D supplementation inhibit ventricular remodelling and improve cardiac function in patients with HF.

Trial registration: PROSPERO CRD42017073893

Keywords: Vitamin D, ventricular remodeling, cardiac function, heart failure

Strengths and limitations of this study

- The results of this systematic review and meta-analysis is highly dependent on the quality of the included primary research studies. Only RCTs were included in this study.
- Subgroup analyses were performed according to clinical heterogeneity analysis of the included studies.
- This was the first review to systematically examine the impact of vitamin D supplementation on ventricular remodelling in patients with heart failure. The results

1
2
3 suggest that vitamin D may be utilized as adjunctive heart failure medication in heart
4
5
6 failure patients with an underlying lack of or insufficiency in vitamin D.
7

8
9 ➤ The results need to be interpreted with caution, as there were few studies in each
10
11 subgroup.
12
13

14 15 16 **Introduction**

17
18 Heart failure(HF) is the main factor leading to economic loss due to poor prognosis
19
20 and a high mortality rate [1]. In the USA, there are at least 5,000,000 patients with
21
22 decreased contractile function; meanwhile, there is also the same number of patients
23
24 with the same disease in Western Europe [2,3]. In recent years, the prognosis of HF
25
26 has improved remarkably, and the 5-year survival rate has increased from 43% to 52%
27
28 [4]. At present, the main treatment methods for HF are still β -receptor blocking agents,
29
30 ACEI/ARB, and aldosterone receptor antagonists; although these medications can
31
32 reduce the incidence of adverse cardiac events and improve cardiac function [5], HF
33
34 is still a main cause of global mortality. Therefore, there is presently an urgent need
35
36 for supplementary treatment methods and strategies.
37
38
39
40
41
42
43
44

45
46 lack of or insufficiency in vitamin D may result in cardiovascular and cerebrovascular
47
48 diseases [6-10]. Many studies have discovered that [11-14] there is a remarkable
49
50 association between lack of vitamin D and the progression of HF. Studies have shown
51
52 that patients with HF generally lack vitamin D and have a poor prognosis; moreover,
53
54 supplementation of vitamin D could reduce the mortality rate of patients with HF
55
56
57

1
2
3 [15-17]. Several studies have shown that vitamin D acts as a negative regulator of the
4
5
6 renin-angiotensin-aldosterone system (RAAS) [18-20] and modulates myocardial
7
8
9 extracellular matrix turnover. Consistently, vitamin D receptor (VDR) knockout mice
10
11
12 show increased RAAS activity, which leads to hypertension, cardiac hypertrophy,
13
14
15 increased water intake and sodium retention [18], and VDR knockout mice show
16
17
18 increased metalloprotease (MMP) activity, which promotes the destruction of
19
20
21 myocardial tissue, leading to ventricular remodelling [21,22]. Therefore, lack of
22
23
24 vitamin D could result in deterioration of heart function and accelerate myocardial
25
26
27 remodelling.

28
29
30 At present, different studies have reported controversial conclusions regarding the
31
32
33 influence of vitamin D on ventricular remodelling in patients with HF. Therefore, the
34
35
36 present study performed a meta-analysis to further clarify the influence of vitamin D
37
38
39 on ventricular remodelling in patients with HF.

40 **Materials and Methods**

41 **Search strategy**

42
43
44 PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CNKI and Web
45
46
47 of Science were searched. Grey literature was also retrieved in Opengrey and
48
49
50 ProQuest. The reference lists of identified articles and the bibliographies of original
51
52
53 articles were also reviewed. The medical subject headings used in the search were as
54
55
56 follows: “heart failure”, “vitamin D”, “ventricular remodelling”, “heart function tests”,
57
58
59

1
2
3 and “randomized controlled trials”. The keywords used in the search were as follows:
4
5
6 “cardiac failure”, “myocardial failure”, “heart decompensation”, “left ventricular
7
8 remodelling”, “ventricular remodelling”, “ventricular myocardial remodelling”,
9
10
11 “cholecalciferol”, “vitamin D3”, and “controlled clinical trials”. The time frame for
12
13 the retrieval was from the establishment of the database to October 1, 2017.
14
15

16 17 18 **Study selection**

19
20 The inclusion criteria were as follows: 1) Randomized controlled trials (RCTs)
21
22 involving the effect of vitamin D on ventricular remodelling in patients with HF with
23
24 or without blinding methods or allocation concealment methods; 2) Parallel or
25
26 crossover trials; 3) Only the data before the washout period were used in a crossover
27
28 test; 4) Available baseline data and changes in the left ventricular end-diastolic
29
30 dimension (LVEDD) and left ventricular ejection fraction (LVEF); 5) HF defined as
31
32 New York Heart Association functional class \geq II or LVEF \leq 40%; 6) Participants of
33
34 any gender, age or ethnicity; 7) Participants without or changing any micronutrient
35
36 use except for vitamin D, and 8) A minimum of 3 months of therapy was necessary
37
38 for inclusion in the review to ensure that the intervention had sufficient time to
39
40 produce a better effect. The exclusion criteria were as follows: 1) Only the abstract
41
42 was reported for reference; 2) Studies with duplicated data, including the same group
43
44 of patients or patients for whom there were updated results available; 3) The study
45
46 had no outcomes of interest 4) Animal studies and reviews; 5) Conference documents;
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and 6) Non-RCTs, cohort studies, and retrospective studies. This study was
4
5
6 conducted in accordance with the Declaration of Helsinki and obtained approval from
7
8 the Ethics Committee of Henan University of Science and Technology.
9

10 11 12 13 **Data extraction and quality assessment**

14
15
16 Data were independently extracted from each study by two authors (JD Zhao and JJ
17
18 Jia) and entered into a structured spreadsheet followed by a cross-check procedure.
19
20 Disagreements were resolved by consensus or by a third investigator (P. Dong). The
21
22 following data were extracted from each trial: the first author's surname, year of
23
24 publication; demographic and methodological data; total number, mean age, gender
25
26 distribution and race of enrolled patients; use of or change in drugs for HF; seated
27
28 LVEDD and LVEF at baseline, when available; number of patients randomly
29
30 assigned to each intervention; duration of therapy; incidence and type of adverse
31
32 events; number of dropouts or withdrawals because of adverse events; and change
33
34 from baseline seated LVEDD and LVEF. Criteria for the RCT risk of bias evaluation
35
36 listed in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 were
37
38 adopted, including the following: 1) random sequence generation, 2) allocation
39
40 concealment, 3) blinding of patients and personnel, 4) blinding of outcome assessment,
41
42 5) incomplete outcome data, and 6) selective reporting risk. Then, an evaluation
43
44 system with "low risk", "high risk" and "not clear" was established according to the
45
46 six criteria described above [23].
47
48
49
50
51
52
53
54
55
56

Outcomes assessed

The primary endpoint was LVEDD, and the secondary endpoints were LVEF and the incidence of adverse reactions.

Data analysis and synthesis

RevMan5.3 software was employed for data analysis. Continuous variables are reported as the mean difference (MD) and 95% CI, and the test level was $\alpha = 0.05$.

Following clinical heterogeneity analysis of the included studies, statistical heterogeneity was assessed using χ^2 -based Cochran Q statistic and I^2 [24]. For the Q statistic, $P \geq 0.1$ indicates homogeneity among multiple similar studies, and the fixed-effects model was employed for the meta-analysis, while $P < 0.1$ indicates statistically significant heterogeneity, and the random-effects model was used for analysis. For the I^2 statistic, $I^2 < 25\%$ indicates low heterogeneity, while $I^2 > 50\%$ indicates moderate to high heterogeneity [25].

Patient and public involvement

All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

Results

Selection and description of studies

A total of 157 published papers were collected after the initial screening, and eventually, seven RCTs [26-32] with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included after reviewing the title, abstract and full text, as well as eliminating duplicate documents, non-RCTs, and studies that failed to meet the inclusion criteria. See **Figure 1** for the screening process.

In the seven included studies [26-32], four studies reported an appropriate randomization method [27-29,32]; two studies adopted allocation concealment [29,32], and six studies used double-blinding [26-30,32]. See **Figure 2** for the evaluation of the methodology of the studies.

Data of the curative effect on the LVEDD were reported in five studies, and the LVEF was reported in all the included studies; two studies mentioned adverse reactions [26,30]. Dropout or withdrawal from the research study was covered in all the included studies. The study characteristics are shown in **Table 1**, and the basic information of the include population is shown in **Table 2**.

Effects of vitamin D on the LVEDD

1
2
3
4 Changes in the LVEDD of patients were reported in five studies [26-30], which
5
6 showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 ,
7
8 $P=0.07$, $I^2=55\%$), thus supporting analysis using the random-effects model. Compared
9
10 with the control group, a decrease in the LVEDD was observed in the vitamin D
11
12 group (mean difference [MD] = -2.31mm, 95% confidence interval [CI]: -4.15- -0.47,
13
14 $P=0.01$) (**Figure 3**).

21 **Effects of vitamin D on the LVEF**

22
23 Changes in the LVEF of patients were reported in all seven studies [26-32], which
24
25 showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 ,
26
27 $P < 0.001$, $I^2=88\%$), thus supporting analysis using the random-effects model.
28
29 Compared with the control group, an increase in the LVEF was observed in the
30
31 vitamin D group (MD=4.18%, 95% CI: 0.36-7.99, $P=0.03$) (**Figure 4**).

39 **Subgroup analysis**

40
41 The analysis based on age stratification revealed that compared with the control group,
42
43 both the adults (aged ≥ 18 years) and non-adults (aged < 18 years) with HF in the
44
45 vitamin D group showed a decrease in the LVEDD (adults: heterogeneity χ^2 , $P=0.65$,
46
47 $I^2=0\%$; MD=-1.62mm, 95% CI: -2.83- -0.42, $P=0.008$; non-adults: MD=-5.51mm, 95%
48
49 CI, -8.08- -2.94, $P < 0.001$) (**Figure 5**). These results, however, need to be interpreted
50
51 with caution, as there was only one study in the subgroup of non-adults.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 A subgroup analysis was performed according to the dosage of vitamin D. There was
7
8 an effect from high-dose vitamin D on the reduction of the LVEDD (heterogeneity χ^2 ,
9
10 $P=0.50$, $I^2=0\%$; MD=-1.71mm, 95% CI: -2.95- -0.46, $P=0.007$), but this effect was
11
12 not seen with low-dose vitamin D treatment (heterogeneity χ^2 , $P=0.06$, $I^2=71\%$;
13
14 MD=-3.38mm, 95% CI: -8.23- 1.48, $P=0.17$). (**Figure 6**).

15
16
17
18
19
20
21 According to patients with or without reduced ejection fraction, subgroup analyses
22
23 were performed. Vitamin D supplementation was effective at reducing the LVEDD in
24
25 patients with reduced ejection fraction (patients with reduced ejection fraction:
26
27 heterogeneity χ^2 , $P=0.07$, $I^2=62\%$; MD=-3.11mm, 95% CI: -5.67- -0.55, $P=0.02$;
28
29 patients without reduced ejection fraction: heterogeneity χ^2 , $P=0.76$, $I^2=0\%$;
30
31 MD=-0.91mm, 95% CI: -2.76- 0.94, $P=0.34$) (**Figure 7**). In addition, vitamin D
32
33 supplementation was effective at increasing the LVEF in patients with reduced
34
35 ejection fraction (patients with reduced ejection fraction: heterogeneity χ^2 , $P=0.02$, I^2
36
37 =73%; MD=6.21%, 95% CI: 2.01- 10.41, $P=0.004$; patients without reduced ejection
38
39 fraction: heterogeneity χ^2 , $P=0.002$, $I^2=80\%$; MD=2.74%, 95% CI: -1.96- 7.45, P
40
41 =0.25) (**Figure 8**).

52 **Publication bias**

53
54
55
56
57
58
59
60

1
2
3
4 There was significant asymmetry in the funnel plot for the effect of vitamin D on the
5
6 LVEDD, which may be due to publication bias and other causes (**Figure 9**). On the
7
8 other hand, no publication bias was found for the effect of vitamin D on the LVEF
9
10
11 (**Figure 10**).
12

13 14 15 16 **Adverse event**

17
18 Two studies [26,30] reported adverse events. During the follow-up, no significant
19
20 adverse event was recorded. No data associated with the incidence of adverse events
21
22 were recorded in the other studies.
23
24
25

26 27 28 **Discussion**

29
30 At present, different studies have reported controversial conclusions regarding the
31
32 influence of vitamin D on ventricular remodelling in patients with HF. The results of
33
34 this study show that compared with the control group, supplementation of vitamin D
35
36 could reduce the LVEDD (MD = -2.31 mm, 95% CI: -4.15- -0.47, P =0.01) and
37
38 improve the LVEF (MD=4.18%, 95% CI: 0.36-7.99, P =0.03) among patients with
39
40 HF. In addition, a more pronounced effect is achieved using high-dose vitamin D and
41
42 on patients with a reduced ejection fraction.
43
44
45
46
47
48
49

50
51 Most new treatment methods for chronic HF are expensive and require advanced
52
53 technologies [33]; in addition, most of these treatment methods have not passed strict
54
55 phase III clinical trials. For patients with HF, vitamin D is not only cheap but also safe,
56
57
58
59

1
2
3 and these patients may obtain more benefits from vitamin D therapy [34]. Vitamin D
4
5
6 toxicity is based not only on the dosing but also on circulating 25OHD levels. The
7
8
9 Institute of Medicine [35] has set the dosage for vitamin D at 4,000IU daily for
10
11 healthy adults, and the Endocrine Society [36] has set a dosage of 10,000IU daily for
12
13 patients who are at risk of having circulating 25OHD levels <50 nmol/L. The Institute
14
15 of Medicine [35] considers circulating 25OHD levels below 30 nmol/L as deficient,
16
17 levels between 30 and 49.99 nmol/L as inadequate, levels between 50 and 125 nmol/L
18
19 as adequate, and levels above 125 nmol/L as potentially harmful. In HF, cardiac
20
21 contraction and diastole are affected due to overload of Ca²⁺ ions in myocardial cells.
22
23 Lack of vitamin D may intervene with the functions of Ca²⁺ in myocardial cells, thus
24
25 resulting in cardiomyocyte hypertrophy and intra-organizational inflammatory
26
27 reaction and fibrosis [37,38]. Low vitamin D levels can activate the renin-angiotensin
28
29 system [39], give rise to inflammatory reactions [40], and result in endothelial
30
31 dysfunction [41]. The effects of vitamin D on the CV system are additionally
32
33 mediated through elevated parathyroid hormone (PTH) levels, which are associated
34
35 with the development of left ventricular (LV) hypertrophy [42]. Although there is
36
37 much evidence showing that a lack of vitamin D could result in poor prognosis among
38
39 patients with HF, different studies have reported controversial conclusions regarding
40
41 whether supplementation of vitamin D could benefit patients with HF.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 In recent years, there some relatively small RCTs have studied the influence of
5
6 vitamin D on patients with HF. In the 2014 World Heart Failure Conference, Louise
7
8 et al [43] reported an RCT that performed a 6-month study on 32 patients with HF,
9
10 and the result showed that supplementation of vitamin D did not improve the LVEF or
11
12 pro-BNP level. A recent meta-analysis [44] also reported that vitamin D
13
14 supplementation could not improve the LVEF (WMD: 4.11%, 95% CI: -0.91 to 9.12,
15
16 P =0.11) and 6-minute walk distance (6MWD) (WMD: 8.90 m, 95% CI: -48.47 to
17
18 66.26, P =0.76) in the treatment of chronic HF. In contrast, this study included three
19
20 other studies, two of which showed a positive effect from vitamin D supplementation.
21
22 The present studies have not shown that vitamin D supplementation can improve the
23
24 6MWD among patients [26,30,45,46]; thus, our meta-analysis did not evaluate this
25
26 parameter. There are probably many factors that affect exercise tolerance, such as
27
28 physical condition, obesity, habits, and environment, and these confounding factors
29
30 may obscure the weak force from the remodelled ventricle. However, other studies
31
32 have drawn opposite conclusions. In 2015, Lowry et al [47] reported in the European
33
34 Society of Cardiology a 12-month RCT, and the result showed that for patients with
35
36 HF, supplementation of vitamin D could improve ventricular remodelling (LVEDD
37
38 -4.46 mm; P =0.047); in addition, the LVEF showed an increasing trend. A non-RCT
39
40 [48] also showed that supplementation of vitamin D could remarkably increase the
41
42 LVEF value compared to baseline. Elidriissy et al [49] evaluated 61 cases of children
43
44 with cardiomyopathy; they concluded, based on the available evidence, that the most
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 likely cause of cardiomyopathy is hypocalcaemia and suggested maternal
4
5
6 supplementation of vitamin D during pregnancy and lactation with up to 2,000 units
7
8
9 of vitamin D and 400 units for their infants for prevention, which was also similar to
10
11 the results reported by Shedeed [29].
12
13
14
15

16 Since there are disputes among different study results, we conducted a meta-analysis
17
18 of relevant RCT studies to further clarify the influence of vitamin D supplementation
19
20 on ventricular remodelling in patients with HF. Results of this study show that
21
22 supplementation of vitamin D inhibit myocardial remodelling and improve cardiac
23
24 function in patients with HF.
25
26
27
28
29
30

31 Different studies have different results and conclusions, which may be attributed to
32
33 the different recommended dosages of vitamin D; since there is no standard
34
35 recommended dosage of vitamin D at present, there are differences in the
36
37 recommended dosage of vitamin D in different trials, which may affect the study
38
39 results. However, there has not been a report related to adverse effects from the
40
41 dosage of vitamin D. Meanwhile, the study results are related to the selected group;
42
43 for example, the study results of Schleithoff et al [28] showed that there were no
44
45 remarkable changes in the LVEF and LVEDD, and the participants included in this
46
47 study were predominantly those with NYHA level 3-4 and a high degree of HF, and
48
49 there was a high rate of lost to follow-up visit (37%).
50
51
52
53
54
55
56

1
2
3
4
5
6 The data on changes in the LVEDD showed high levels of heterogeneity among
7
8 studies. Shedeed [29] studied the cause of heterogeneity according to subgroup. There
9
10 was a difference in the metabolism of vitamin D and cardiac recovery capacity
11
12 between new-borns and adults, which might be the cause of heterogeneity.
13
14
15

16
17
18 Although all trials included in this study are RCTs, there are still many limitations in
19
20 this study: 1) because the current studies found that vitamin D has a weak and
21
22 uncertain effect on ventricular remodelling and cardiac function in patients with HF
23
24 and cannot improve exercise tolerance or reduce cardiac mortality, additional
25
26 large-scale clinical studies are needed. Future research needs to focus on whether
27
28 different vitamin D dosages would be superior; in addition, different selection criteria
29
30 need to be defined (for example, ejection fraction, vitamin D threshold, PTH threshold,
31
32 etc.) and additional echocardiographic parameters, the 6MWD and cardiovascular
33
34 mortality need to be evaluated; 2) this study exhibits heterogeneity, and age
35
36 stratification and whether there is reduced ejection fraction may be sources of clinical
37
38 heterogeneity according to the subgroup analysis; 3) different recommended dosages
39
40 of vitamin D are reported in different trials, which may affect study results; therefore,
41
42 additional trials are required to explore the relationship between vitamin D dosage and
43
44 effect; 4) the conclusions need to be interpreted with caution, as the extent of detected
45
46 improvement in the remodelling parameters is close to the range of the inter- or
47
48
49
50
51
52
53
54
55
56

1
2
3
4 intra-observer variability of the echocardiographic method itself. The baseline vitamin
5
6 D level of patients and the follow-up duration may affect the study results, and except
7
8 for Dalbeni et al [27], whom have mentioned that no change in therapy was made
9
10 during follow-up, other studies have not reported adjustments in HF medication.
11
12 Therefore, whether the weak improvement in the remodelling parameters from
13
14 vitamin D are attributed to other HF drugs is unclear.
15
16
17
18
19
20

21 In conclusion, this study shows that supplementation of vitamin D inhibit myocardial
22
23 remodelling in patients with HF and improve their cardiac function. Vitamin D may
24
25 be utilized as adjunctive HF medication for HF patients with an underlying lack of or
26
27 insufficiency in vitamin D. This result is encouraging and of great clinical interest but
28
29 still far from practical implications. The main implication is to encourage further
30
31 research.
32
33
34
35
36
37
38

39 **Figure legends**

40
41
42 **Figure 1** Flow diagram of study selection.

43
44 **Figure 2** Quality assessment.

45
46
47 **Figure 3** Forest plot showing the effect of Vitamin D on LVEDD.

48
49 **Figure 4** Forest plot showing the effect of Vitamin D on LVEF.

50
51
52 **Figure 5** Subgroup analysis of effect of Vitamin D on LVEDD according to patients'
53
54 age.
55
56

1
2
3
4 **Figure 6** Subgroup analysis of effect of Vitamin D on LVEDD according to dose of
5
6 Vitamin D.
7

8 **Figure 7** Subgroup analysis of effect of Vitamin D on LVEDD according to patients
9
10 with or without reduced ejection fraction.
11
12

13 **Figure 8** Subgroup analysis of effect of Vitamin D on LVEF according to patients
14
15 with or without reduced ejection fraction.
16
17

18 **Figure 9** Funnel plots for the effect of Vitamin D on LVEDD
19
20

21 **Figure 10** Funnel plots for the effect of Vitamin D on LVEF.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Study characteristics.

Author	Design	Blinding	Vitamin D Dose	Follow-up Duration	Study population	Primary Outcome
Turrini et al, 2017	Prospective RCT	Double-blind	300.000 IU at Baseline 50.000IU/mo	6 mo	Chronic HF, 25(OH)D <20 ng/mL, 60 y<Age,	6MWD, echocardiography Parameters, hormonal
Witte et al, 2016	Prospective RCT	Double-blind	4000IU/d	12 mo	Chronic HF, NYHA class II–III, LVEF<45%, 25(OH)D <20 ng/mL	6MWD, echocardiography parameters
Qu et al, 2015	Prospective RCT	Single-blind	1000 IU/d	3 mo	NYHA class III–IV	echocardiography parameters, BNP, 25(OH)D
Dalbeni et	Prospective	Double-blind	4000IU/d	25 wk	Chronic HF, LVEF<55%,	Echocardiographic parameters,

al, 2014	RCT					NYHA class>II, 25(OH)D <30ng/mL, Age >40 y,	NYHA class, NT-proBNP
Boxer er al,2014	Prospective RCT	Double-blind	50000IU/wk	6mo		Age ≥50 y, NYHA class II–IV, 25(OH)D <37.5 ng/mL	Echocardiographic parameters, serum analysis, urine analysis
Shedeed, 2012	Prospective RCT	Double-blind	1000 IU/d	12 wk		Congestive HF, LVEF<40%, LV>2 SD for age and sex	Echocardiographic parameters
Schleithoff et al, 2006	Prospective RCT	Double-blind	2000 IU/d	9 mo		Chronic HF, NYHA class II–IV	Survival rates, NT-proBNP, Pro-and anti-inflammatory cytokines, Echocardiographic parameters,

†25(OH)D; ‡6MWD; §HF; **IU; ††LV; ‡‡LVEF; §§NT-proBNP; ***NYHA;

† 25-hydroxyvitamin D

‡ 6-minute walk distance

§ heart failure

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2 Study population characteristics.

Intervention Number	Age	Male	LVEF (%)	NYHA	NYHA	NYHA	LVEDD	25(OH)D	Ischemic Hypertension	Diabetes (%)
---------------------	-----	------	----------	------	------	------	-------	---------	-----------------------	--------------

** international units
 †† left ventricular
 †† left ventricular ejection fraction
 § § N-terminal pro-B-type natriuretic peptide
 *** New York Heart Association

Author	(n)	(years)	(%)		Class	Class	Class	(mm)	(ng/mL)	Cause	(%)		
					II(%)	III(%)	IV(%)			(%)			
Turrini et al, 2017	Vitamin D	17	77±7	35.3	54.7±13.8	64.7	35.3	0	51±1.58	9.4±5.2	41.2	64.7	35.3
	Placebo	16	79±7	43.8	49.2±19.1	68.7	21.3	0	54±3.48	9.6±7.3	43.7	43.7	18.7
Witte et al, 2016	Vitamin D	80	68.5±12.45	83.8	25.6±10.80	92.5	7.5	0	57.6±8.62	38.2±24.81	55.0	NR	21.3
	Placebo	83	69.0±13.78	74.7	26.5±10.62	85.5	14.5	0	58.0±6.49	36.4±20.24	60.2	NR	24.1
Qu et al, 2015	Vitamin D	22	70±7	59.3	34.9±3.8	NR	NR	NR	NR	NR	NR	66.7	81.5
	Blank	17	69±8	51.8	34.6±3.9	NR	NR	NR	NR	NR	NR	63.0	85.2
Dalbeni et al, 2014	Vitamin D	13	71.2±6.22	84.6	39.08±8.00	58.8*	50.0**		53.9±6.81	16.2±6.59	76.9	100	NR
	Placebo	10	73.4±13.78	60.0	43.6±7.63	41.2*	50.0**		50.6±7.04	16.0±6.15	90	100	NR
Boxer et al, 2014	Vitamin D	19	65.8±10.6	48.4	39.2±13.2	55.0	73.0	0	NR	19.1±9.3	25.8	83.0	51.6
	Placebo	15	66.0±10.4	54.5	36.1±14.5	45.0	27.0	0	NR	17.8±9.0	30.3	84.8	42.4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Shedeed,	Vitamin D	42	0.86±1.3	64.29	36.4±2.26	NR	NR	NR	32.81±4.6	13.4±2.21	NR	NR	NR
2012	Placebo	38	0.93±1.0	57.89	37.2±2.62	NR	NR	NR	30.7±5.2	14.0±2.46	NR	NR	NR
	Vitamin D+						NR	NR			47	38	20
Schleithoff	Calcium	42	57±7.41	85.25	32.5±8.67	NR			69.0±8.89	14.4±7.85			
et al, 2006	Placebo+						NR	NR			40	32	23
	Calcium	51	54±8.89	80.65	33.0±7.56	NR			69.0±9.26	15.3±7.48			

†††NR

Review only

††† Not reported
 *I and II
 ** III and IV

Contributor ship statement

Jin-Dong Zhao: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND Drafting the work or revising it critically for important intellectual content; AND Final approval of the version to be published; AND Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Jing-Jing Jia: participated in writing

Ping-Shuan Dong * : served as scientific advisors

Di Zhao: participated in technical editing of the manuscript

Xu-Ming Yang: critically reviewed the study proposal

Dao-Lin Li: collected data

Hui-Feng Zhang: collected data

Disclosure of conflict of interest

None.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

The authors declare that they willing to share their data directly.

References

1. Mengchao Jin, Siqi Wei, Rongrong Gao, et al. Predictors of Long-Term Mortality in Patients With Acute Heart Failure. *Int Heart J* 2017; 58: 409-15.
2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013; 6 : 606–19.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007; 93: 1137–46.
4. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004; 292: 344-50.
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012; 14: 803-69
6. Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. *Am J Clin Nutr* 2011; 94: 534-42

- 1
2
3
4 7. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. *Curr*
5
6 *Opin Nephrol Hypertens* 2012; 21: 492–9.
- 7
8
9 8. Karakas M, Thorand B, Zierer A, et al. Low levels of serum 25-hydroxyvitamin
10
11 D are associated with increased risk of myocardial infarction, especially in
12
13 women: results from the MONICA/KORA Augsburg case-cohort study. *J Clin*
14
15 *Endocrinol Metab* 2013; 98: 272–80.
- 16
17
18 9. Sun Q, Pan A, Hu FB, et al. 25-Hydroxyvitamin D levels and the risk of stroke: a
19
20 prospective study and meta-analysis. *Stroke* 2012; 43: 1470–7.
- 21
22
23 10. Desai CK, Huang J, Lokhandwala A, et al. The role of vitamin supplementation
24
25 in the prevention of cardiovascular disease events. *Clin Cardiol* 2014; 37: 576–
26
27 81
- 28
29
30 11. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin
31
32 D—markers for cardiovascular and all cause mortality in heart failure. *Eur J*
33
34 *Heart Fail* 2011; 13: 626–32.
- 35
36
37 12. Liu L, Chen Chen M, Hankins SR, et al. Serum 25-hydroxyvitamin D
38
39 concentration and mortality from heart failure and cardiovascular disease, and
40
41 premature mortality from all-cause in United States adults. *Am J Cardiol* 2012;
42
43 110: 834–9.
- 44
45
46 13. Ford JA, MacLennan GS, Avenell A, et al. Cardiovascular disease and vitamin D
47
48 supplementation: trial analysis, systematic review, and meta-analysis. *Am J Clin*
49
50 *Nutr* 2014; 100: 746–55.
- 51
52
53
54
55
56

- 1
2
3
4 14. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk
5
6 of cardiovascular disease : a meta-analysis of prospective studies. *Circ*
7
8 *Cardiovasc Qual Outcomes* 2012; 5: 819–29.
9
- 10
11 15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment and
12
13 prevention of vitamin D deficiency: an Endocrine Society clinical practice guide.
14
15 *J Clin Endocrinol Metab* 2011; 96: 1911-30.
16
- 17
18 16. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of
19
20 reduced survival in patients with heart failure; vitamin D supplementation
21
22 improves outcome. *Eur J Heart Fail* 2012; 14: 357–66
23
- 24
25 17. Pourdjabbar A, Dwivedi G, Haddad H. The role of vitamin D in chronic heart
26
27 failure. *Curr Opin Cardiol.* 2013; 28: 216–22.
28
- 29
30 18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3)
31
32 is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest*
33
34 2002; 110: 229e38.
35
- 36
37 19. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al.
38
39 Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin
40
41 D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular
42
43 Health (LURIC) Study. *Clin Chim Acta* 2010; 411: 1354e60.
44
45
- 46
47 20. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and
48
49 regulation of the renin-angiotensin system in humans. *Hypertension* 2010; 55:
50
51 1283e8.
52
53
54
55
56

- 1
2
3
4 21. Weber KT, Weglicki WB, Simpson RU. Macro- and micronutrient
5
6 dyshomeostasis in the adverse structural remodeling of myocardium. *Cardiovasc*
7
8 *Res* 2009; 81: 500e8.
9
- 10
11 22. Agarwal M, Phan A, Willix Jr R, Barber M, Schwarz ER. Is vitamin D
12
13 deficiency associated with heart failure? A review of current evidence. *J*
14
15 *Cardiovasc Pharmacol Ther.* 2011; 16: 354e63.
16
- 17
18 23. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of*
19
20 *Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,*
21
22 2011. Available at: www.cochrane-hand-book.org.
23
24
- 25
26 24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in
27
28 meta-analyses. *BMJ* 2003; 327: 557-60.
29
- 30
31 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat*
32
33 *Med* 2002; 21: 1539–58.
34
35
- 36
37 26. Turrini F, Scarlini S, Giovanardi P, et al.
38
39 Effects of cholecalciferol supplementation in patients with stable heart failure an
40
41 d low vitamin D levels (ECSPLOIT-D). A double-blind, randomized, placebo-con
42
43 trolled pilot study. *Minerva Cardioangiol* 2017 DOI:
44
45 10.23736/S0026-4725.17.04340-7
46
47
48
- 49
50 27. Dalbeni A, Scaturro G, Degan M, et al. Effects of six months of vitamin D
51
52 supplementation in patients with heart failure: a randomized double-blind
53
54 controlled trial. *Nutr Metab Cardiovasc Dis* 2014; 24: 861–8.
55
56

- 1
2
3
4 28. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation
5
6 improves cytokine profiles in patients with congestive heart failure: a
7
8 double-blind, randomized, placebocontrolled trial. *Am J Clin Nutr* 2006; 83:
9
10 754–9.
11
- 12
13
14 29. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart
15
16 failure. *Pediatr Cardiol* 2012; 33: 713–9.
17
- 18
19 30. Witte KK, Byrom R, Gierula J, et al. Effects of vitamin D on cardiac function in
20
21 patients with chronic HF: the VINDICATE study. *J Am Coll Cardiol* 2016; 67:
22
23 2593-603.
24
- 25
26 31. Qu Jun, Wang Zhen, Song hong-bo, et al. The Clinical Effect of Vitamin D 3
27
28 Supplementation on Cardiac Function in Patients with Ischemic Heart Failure.
29
30 *Chinese and Foreign Medical Research*, 2015, 13: 3-5.
31
32
- 33
34 32. Boxer RS, Hoit BD, Schmotzer BJ, et al. The effect of vitamin D on aldosterone
35
36 and health status in patients with heart failure. *J Card Fail* 2014; 20: 334–42
37
38
- 39
40 33. Rie Amai, Teruhiko Imamura, Yasuo Nakahara, et al. Reversible Motor
41
42 Paralysis and Early Cardiac Rehabilitation in Patients With Advanced Heart
43
44 Failure Receiving Left Ventricular Assist Device Therapy. *Int Heart J* 2016; 57:
45
46 766-8
47
48
- 49
50 34. Witte KK, Byrom R. Micronutrients for chronic heart failure: end of the road or
51
52 path to enlightenment? *J Am Coll Cardio HF* 2014; 2: 318–20.
53
54
55
56
57
58
59
60

- 1
2
3
4 35. Institute of Medicine. Dietary Reference Intakes: Calcium and Vitamin D.
5
6 Washington, DC: National Academies Press; 2011.
7
8
9 36. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and
10
11 prevention of vitamin D deficiency: an Endocrine Society clinical practice
12
13 guideline. *J Clin Endocrinol Metab* 2011; 96: 1911-30.
14
15
16 37. Weisshaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular
17
18 function II direct and indirect effects. *Am J Physiol* 1987; 253: E675-83
19
20
21 38. Chen S, Law CS, Grigsby CL, et al. Cardiomyocyte-specific deletion of the
22
23 vitamin D receptor gene results in cardiac hypertrophy. *Circulation* 2011; 124:
24
25 1838-47.
26
27
28
29 39. Vaidya A, Williams JS. The relationship between vitamin D and the renin
30
31 angiotensin system in the pathophysiology of hypertension, kidney disease, and
32
33 diabetes. *Metabolism* 2012; 61: 450-8.
34
35
36
37 40. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits
38
39 monocyte/macrophage proinflammatory cytokine production by targeting MAPK
40
41 phosphatase-1. *J Immunol* 2012; 188: 2127-35.
42
43
44
45 41. Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial
46
47 function and dysfunction. *Arch Med Sci* 2012; 8: 4-5.
48
49
50 42. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left
51
52 ventricular hypertrophy. *Eur Heart J* 2003; 24: 2054e60.
53
54
55
56
57
58
59
60

- 1
2
3
4 43. LLLouise Schierbeck, J L Madsen, U C Bang, et al. The effect of vitamin D
5
6 supplementation in vitamin D deficient men with heart failure. A randomized
7
8 controlled trial.:P1686. European journal of heart failure 2014, 16, 335 Online
9
10
11 Publication Date: 2014
12
13
14 44. Jiang WL, Gu HB, Zhang YF, et al. Vitamin D Supplementation in the
15
16 Treatment of Chronic Heart Failure: A Meta-analysis of Randomized Controlled
17
18 Trials. Clin Cardiol 2016; 39: 56-61.
19
20
21 45. Boxer RS, Kenny AM, Schmotzer BJ, et al. A randomized controlled trial of
22
23 high dose vitamin D3 in patients with heart failure. JACC Heart Fail 2013; 1:
24
25 84-90.
26
27
28
29 46. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D
30
31 supplementation on physical function and quality of life in older patients with
32
33 heart failure: a randomized controlled trial. Circ Heart Fail 2010; 3: 195–201.
34
35
36
37 47. Lowry J , Gierula J , Byrom R, et al. Vitamin D supplementation improves the
38
39 size and function of the left ventricle in patients with heart failure . European
40
41 heart journal 2015, 36, 665 Online Publication Date: 2016
42
43
44 48. Zia AA, Komolafe BO, Moten M, et al. Supplemental vitamin D and calcium in
45
46 the management of African Americans with heart failure having hypovitaminosis
47
48 D. Am J Med Sci 2011;341:113-118.
49
50
51
52 49. Elidrissy AT, MunawarahM, Alharbi KM. Hypocalcemic rachitic
53
54 cardiomyopathy in infants. J Saudi Heart Assoc 2013; 25: 25-33.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Flow diagram of study selection.

176x155mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Boxer 2014	+	+	?	+	+	+
Dalbeni 2014	+	?	+	+	+	+
Qu 2015	?	?	?	+	+	+
Schleithoff 2006	+	?	?	+	+	+
Shedeed 2012	+	+	+	+	+	+
Turrini 2017	?	?	+	+	+	+
Witte 2016	?	?	+	+	+	+

Figure 2 Quality assessment.

422x794mm (300 x 300 DPI)




Figure 3 Forest plot showing the effect of Vitamin D on LVEDD.

92x20mm (300 x 300 DPI)




Figure 4 Forest plot showing the effect of Vitamin D on LVEF.

92x24mm (300 x 300 DPI)




Figure 5 Subgroup analysis of effect of Vitamin D on LVEDD according to patients' age.

44x17mm (300 x 300 DPI)




Figure 6 Subgroup analysis of effect of Vitamin D on LVEDD according to dose of Vitamin D.

88x34mm (300 x 300 DPI)




Figure 7 Subgroup analysis of effect of Vitamin D on LVEDD according to patients with or without reduced ejection fraction.

118x46mm (300 x 300 DPI)




Figure 8 Subgroup analysis of effect of Vitamin D on LVEF according to patients with or without reduced ejection fraction.

129x55mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 9 Funnel plots for the effect of Vitamin D on LVEDD

105x70mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 10 Funnel plots for the effect of Vitamin D on LVEF.

105x70mm (300 x 300 DPI)

view only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	4
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	8
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	9
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	9
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	9



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	9
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	9
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	10
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	10
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	11
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	11
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	12
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	23

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

BMJ Open

Effect of Vitamin D on Ventricular Remodeling in Heart Failure: A Meta-analysis of Randomized Controlled Trials.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020545.R2
Article Type:	Research
Date Submitted by the Author:	13-Jun-2018
Complete List of Authors:	<p>zhao, jindong; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China,</p> <p>Jia, JingJing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Dong, PingShuan; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhao, Di; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Yang, XuMing; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Li, DaoLin; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p> <p>Zhang, HuiFeng; Department of Cardiology, the First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003, China</p>
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Evidence based practice, Cardiovascular medicine
Keywords:	Meta-analysis, Vitamin D, ventricular remodeling, cardiac function, Heart failure < CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4 **Effect of Vitamin D on Ventricular Remodeling in Heart Failure: A**
5
6 **Meta-analysis of Randomized Controlled Trials**
7
8
9

10 **Running title:** Vitamin D treatment of Heart Failure
11

12
13 **Jin-Dong Zhao, Jing-Jing Jia, Ping-Shuan Dong^{*}, Di Zhao, Xu-Ming Yang,**
14
15

16 **Dao-Lin Li, Hui-Feng Zhang**
17
18

19
20 **Author:** Jin-Dong Zhao, Department of Cardiology, The First Affiliated Hospital, and
21

22 College of Clinical Medicine of Henan University of Science and Technology,
23

24
25 Luoyang 471003, China. Tel: 18437919892;
26

27
28 E-mail: zhaojindong123@outlook.com
29
30

31
32
33 ***Corresponding author:** Ping-Shuan Dong, Department of Cardiology, The First
34

35 Affiliated Hospital, and College of Clinical Medicine of Henan University of Science
36

37 and Technology, Luoyang 471003, China. E-mail: pingshuandong@foxmail.com
38
39

40
41
42 **Address of all author:** The First Affiliated Hospital, and College of Clinical
43

44 Medicine of Henan University of Science and Technology, Luoyang 471003, China.
45
46

47
48
49 **Abstract: 291**
50

51
52
53
54 **Main text: 2900**
55
56

ABSTRACT:

Objectives: The level of vitamin D is considered to be associated with the development and progression of heart failure(HF). However, it is still unclear whether supplementation of vitamin D could improve ventricular remodelling in patients with HF. This study aimed to systematically evaluate the influence and safety of additional vitamin D supplementation on ventricular remodelling in patients with HF.

Design: This study is a meta-analysis of randomized controlled trials.

Setting: The PubMed, EMBASE, CNKI, Cochrane library, Web of Science databases and grey literature were searched for randomized controlled trials (RCTs) regarding the effect of vitamin D on ventricular remodelling in patients with HF (from database creation to October 2017). RevMan5.3 software was employed for data analysis.

Participants: Seven RCTs with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included.

Primary and secondary outcome measures: Left ventricular end-diastolic dimension(LVEDD), left ventricular ejection fraction(LVEF), and the incidence of adverse reactions.

Results: Compared with the control group, a decrease in the LVEDD (mean difference [MD] =-2.31mm, 95% confidence interval [CI]: -4.15- -0.47, P =0.01) and an increase in the LVEF (MD=4.18%, 95% CI: 0.36-7.99, P =0.03) were observed in the vitamin D group. Subgroup analysis also revealed a reduced LVEDD in adults

(>18 years) and adolescents (<18 years) of the vitamin D group relative to that in those of the control group. High-dose vitamin D (>4,000IU/day) was more effective at reducing the LVEDD than low-dose vitamin D (<4,000IU/day). Moreover, vitamin D supplementation was more effective at reducing the LVEDD and increasing the LVEF in patients with reduced ejection fraction than in patients without reduced ejection fraction.

Conclusion: Vitamin D supplementation inhibit ventricular remodelling and improve cardiac function in patients with HF.

Trial registration: PROSPERO CRD42017073893

Keywords: Vitamin D, ventricular remodeling, cardiac function, heart failure

Strengths and limitations of this study

- The results of this systematic review and meta-analysis is highly dependent on the quality of the included primary research studies. Only RCTs were included in this study.
- Subgroup analyses were performed according to clinical heterogeneity analysis of the included studies.
- This was the first review to systematically examine the impact of vitamin D supplementation on ventricular remodelling in patients with heart failure. The results

1
2
3 suggest that vitamin D may be utilized as adjunctive heart failure medication in heart
4
5
6 failure patients with an underlying lack of or insufficiency in vitamin D.

7
8 ➤ The results need to be interpreted with caution, as there were few studies in each
9
10 subgroup.
11
12
13

14 15 16 **Introduction**

17
18 Heart failure(HF) is the main factor leading to economic loss due to poor prognosis
19
20 and a high mortality rate [1]. In the USA, there are at least 5,000,000 patients with
21
22 decreased contractile function; meanwhile, there is also the same number of patients
23
24 with the same disease in Western Europe [2,3]. In recent years, the prognosis of HF
25
26 has improved remarkably, and the 5-year survival rate has increased from 43% to 52%
27
28 [4]. At present, the main treatment methods for HF are still β -receptor blocking agents,
29
30 ACEI/ARB, and aldosterone receptor antagonists; although these medications can
31
32 reduce the incidence of adverse cardiac events and improve cardiac function [5], HF
33
34 is still a main cause of global mortality. Therefore, there is presently an urgent need
35
36 for supplementary treatment methods and strategies.
37
38
39
40
41
42
43
44

45
46 lack of or insufficiency in vitamin D may result in cardiovascular and cerebrovascular
47
48 diseases [6-10]. Many studies have discovered that [11-14] there is a remarkable
49
50 association between lack of vitamin D and the progression of HF. Studies have shown
51
52 that patients with HF generally lack vitamin D and have a poor prognosis; moreover,
53
54 supplementation of vitamin D could reduce the mortality rate of patients with HF
55
56
57
58
59
60

1
2
3 [15-17]. Several studies have shown that vitamin D acts as a negative regulator of the
4
5
6 renin-angiotensin-aldosterone system (RAAS) [18-20] and modulates myocardial
7
8
9 extracellular matrix turnover. Consistently, vitamin D receptor (VDR) knockout mice
10
11
12 show increased RAAS activity, which leads to hypertension, cardiac hypertrophy,
13
14
15 increased water intake and sodium retention [18], and VDR knockout mice show
16
17
18 increased metalloprotease (MMP) activity, which promotes the destruction of
19
20
21 myocardial tissue, leading to ventricular remodelling [21,22]. Therefore, lack of
22
23
24 vitamin D could result in deterioration of heart function and accelerate myocardial
25
26
27 remodelling.

28
29
30 At present, different studies have reported controversial conclusions regarding the
31
32
33 influence of vitamin D on ventricular remodelling in patients with HF. Therefore, the
34
35
36 present study performed a meta-analysis to further clarify the influence of vitamin D
37
38
39 on ventricular remodelling in patients with HF.

40 **Materials and Methods**

41 **Search strategy**

42
43
44 PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CNKI and Web
45
46
47 of Science were searched. Grey literature was also retrieved in Opengrey and
48
49
50 ProQuest. The reference lists of identified articles and the bibliographies of original
51
52
53 articles were also reviewed. The medical subject headings used in the search were as
54
55
56 follows: “heart failure”, “vitamin D”, “ventricular remodelling”, “heart function tests”,
57
58
59

1
2
3 and “randomized controlled trials”. The keywords used in the search were as follows:
4
5
6 “cardiac failure”, “myocardial failure”, “heart decompensation”, “left ventricular
7
8 remodelling”, “ventricular remodelling”, “ventricular myocardial remodelling”,
9
10
11 “cholecalciferol”, “vitamin D3”, and “controlled clinical trials”. The time frame for
12
13 the retrieval was from the establishment of the database to October 1, 2017.
14
15

16 17 18 **Study selection**

19
20 The inclusion criteria were as follows: 1) Randomized controlled trials (RCTs)
21
22 involving the effect of vitamin D on ventricular remodelling in patients with HF with
23
24 or without blinding methods or allocation concealment methods; 2) Parallel or
25
26 crossover trials; 3) Only the data before the washout period were used in a crossover
27
28 test; 4) Available baseline data and changes in the left ventricular end-diastolic
29
30 dimension (LVEDD) and left ventricular ejection fraction (LVEF); 5) HF defined as
31
32 New York Heart Association functional class \geq II or LVEF \leq 40%; 6) Participants of
33
34 any gender, age or ethnicity; 7) Participants without or changing any micronutrient
35
36 use except for vitamin D, and 8) A minimum of 3 months of therapy was necessary
37
38 for inclusion in the review to ensure that the intervention had sufficient time to
39
40 produce a better effect. The exclusion criteria were as follows: 1) Only the abstract
41
42 was reported for reference; 2) Studies with duplicated data, including the same group
43
44 of patients or patients for whom there were updated results available; 3) The study
45
46 had no outcomes of interest 4) Animal studies and reviews; 5) Conference documents;
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and 6) Non-RCTs, cohort studies, and retrospective studies. This study was
4
5
6 conducted in accordance with the Declaration of Helsinki and obtained approval from
7
8 the Ethics Committee of Henan University of Science and Technology.
9

10 11 12 13 **Data extraction and quality assessment**

14
15
16 Data were independently extracted from each study by two authors (JD Zhao and JJ
17
18 Jia) and entered into a structured spreadsheet followed by a cross-check procedure.
19
20 Disagreements were resolved by consensus or by a third investigator (P. Dong). The
21
22 following data were extracted from each trial: the first author's surname, year of
23
24 publication; demographic and methodological data; total number, mean age, gender
25
26 distribution and race of enrolled patients; use of or change in drugs for HF; seated
27
28 LVEDD and LVEF at baseline, when available; number of patients randomly
29
30 assigned to each intervention; duration of therapy; incidence and type of adverse
31
32 events; number of dropouts or withdrawals because of adverse events; and change
33
34 from baseline seated LVEDD and LVEF. Criteria for the RCT risk of bias evaluation
35
36 listed in the Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 were
37
38 adopted, including the following: 1) random sequence generation, 2) allocation
39
40 concealment, 3) blinding of patients and personnel, 4) blinding of outcome assessment,
41
42 5) incomplete outcome data, and 6) selective reporting risk. Then, an evaluation
43
44 system with "low risk", "high risk" and "not clear" was established according to the
45
46 six criteria described above [23].
47
48
49
50
51
52
53
54
55
56

Outcomes assessed

The primary endpoint was LVEDD, and the secondary endpoints were LVEF and the incidence of adverse reactions.

Data analysis and synthesis

RevMan5.3 software was employed for data analysis. Continuous variables are reported as the mean difference (MD) and 95% CI, and the test level was $\alpha = 0.05$.

Following clinical heterogeneity analysis of the included studies, statistical heterogeneity was assessed using χ^2 -based Cochran Q statistic and I^2 [24]. For the Q statistic, $P \geq 0.1$ indicates homogeneity among multiple similar studies, and the fixed-effects model was employed for the meta-analysis, while $P < 0.1$ indicates statistically significant heterogeneity, and the random-effects model was used for analysis. For the I^2 statistic, $I^2 < 25\%$ indicates low heterogeneity, while $I^2 > 50\%$ indicates moderate to high heterogeneity [25].

Patient and public involvement

All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

Results

Selection and description of studies

A total of 157 published papers were collected after the initial screening, and eventually, seven RCTs [26-32] with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included after reviewing the title, abstract and full text, as well as eliminating duplicate documents, non-RCTs, and studies that failed to meet the inclusion criteria. See **Figure 1** for the screening process.

In the seven included studies [26-32], four studies reported an appropriate randomization method [27-29,32]; two studies adopted allocation concealment [29,32], and six studies used double-blinding [26-30,32]. See **Figure 2** for the evaluation of the methodology of the studies.

Data of the curative effect on the LVEDD were reported in five studies, and the LVEF was reported in all the included studies; two studies mentioned adverse reactions [26,30]. Dropout or withdrawal from the research study was covered in all the included studies. The study characteristics are shown in **Table 1**, and the basic information of the include population is shown in **Table 2**.

The standard deviations for changes from baseline on the LVEF were reported in four studies [27,28,30,32]. According to the Cochrane Handbook, the Corr were imputed

1
2
3
4 by averaging the Corr of those four studies, and further imputed the standard
5
6 deviations for changes from baseline for other studies [26,29,31].
7
8
9

10
11 The standard deviations for changes from baseline on the LVEDD were reported in
12
13 three studies [27,28,30]. According to the Cochrane Handbook, the Corr were
14
15 imputed by averaging the Corr of those three studies, and further imputed the standard
16
17 deviations for changes from baseline for other studies [26,29].
18
19
20
21
22
23

24 **Effects of vitamin D on the LVEDD**

25
26 Changes in the LVEDD of patients were reported in five studies [26-30], which
27
28 showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 ,
29
30 $P=0.07$, $I^2=55\%$), thus supporting analysis using the random-effects model. Compared
31
32 with the control group, a decrease in the LVEDD was observed in the vitamin D
33
34 group (mean difference [MD] = -2.31mm, 95% confidence interval [CI]: -4.15- -0.47,
35
36
37 $P =0.01$) (Figure 3).
38
39
40
41
42
43

44 **Effects of vitamin D on the LVEF**

45
46 Changes in the LVEF of patients were reported in all seven studies [26-32], which
47
48 showed high levels of heterogeneity among the results of the studies (heterogeneity χ^2 ,
49
50 $P <0.001$, $I^2=88\%$), thus supporting analysis using the random-effects model.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Compared with the control group, an increase in the LVEF was observed in the
5
6 vitamin D group (MD=4.18%, 95% CI: 0.36-7.99, P =0.03) (**Figure 4**).
7
8
9

10 11 **Subgroup analysis**

12
13 The analysis based on age stratification revealed that compared with the control group,
14
15 both the adults (aged \geq 18 years) and non-adults (aged<18 years) with HF in the
16
17 vitamin D group showed a decrease in the LVEDD (adults: heterogeneity χ^2 , P =0.65,
18
19 $I^2=0\%$; MD=-1.62mm, 95% CI: -2.83- -0.42, P =0.008; non-adults: MD=-5.51mm, 95%
20
21 CI, -8.08- -2.94, P<0.001) (**Figure 5**). These results, however, need to be interpreted
22
23 with caution, as there was only one study in the subgroup of non-adults.
24
25
26
27
28
29
30

31 A subgroup analysis was performed according to the dosage of vitamin D. There was
32
33 an effect from high-dose vitamin D on the reduction of the LVEDD (heterogeneity χ^2 ,
34
35 P =0.50, $I^2=0\%$; MD=-1.71mm, 95% CI: -2.95- -0.46, P =0.007), but this effect was
36
37 not seen with low-dose vitamin D treatment (heterogeneity χ^2 , P =0.06, $I^2=71\%$;
38
39 MD=-3.38mm, 95% CI: -8.23- 1.48, P =0.17). (**Figure 6**).
40
41
42
43
44
45
46

47 According to patients with or without reduced ejection fraction, subgroup analyses
48
49 were performed. Vitamin D supplementation was effective at reducing the LVEDD in
50
51 patients with reduced ejection fraction (patients with reduced ejection fraction:
52
53 heterogeneity χ^2 , P =0.07, $I^2=62\%$; MD=-3.11mm, 95% CI: -5.67- -0.55, P =0.02;
54
55
56
57
58
59
60

1
2
3 patients without reduced ejection fraction: heterogeneity χ^2 , P =0.76, I²=0%;
4
5 MD=-0.91mm, 95% CI: -2.76- 0.94, P =0.34) (**Figure 7**). In addition, vitamin D
6
7 supplementation was effective at increasing the LVEF in patients with reduced
8
9 ejection fraction (patients with reduced ejection fraction: heterogeneity χ^2 , P =0.02, I²
10
11 =73%; MD=6.21%, 95% CI: 2.01- 10.41, P =0.004; patients without reduced ejection
12
13 fraction: heterogeneity χ^2 , P =0.002, I²=80%; MD=2.74%, 95% CI: -1.96- 7.45, P
14
15 =0.25) (**Figure 8**).

26 **Publication bias**

27 There was significant asymmetry in the funnel plot for the effect of vitamin D on the
28
29 LVEDD, which may be due to publication bias and other causes (**Figure 9**). On the
30
31 other hand, no publication bias was found for the effect of vitamin D on the LVEF
32
33 (**Figure 10**).

39 **Adverse event**

40
41 Two studies [26,30] reported adverse events. During the follow-up, no significant
42
43 adverse event was recorded. No data associated with the incidence of adverse events
44
45 were recorded in the other studies.
46
47
48
49

51 **Discussion**

52
53 At present, different studies have reported controversial conclusions regarding the
54
55 influence of vitamin D on ventricular remodelling in patients with HF. The results of
56
57

1
2
3
4 this study show that compared with the control group, supplementation of vitamin D
5
6 could reduce the LVEDD (MD = -2.31 mm, 95% CI: -4.15- -0.47, P =0.01) and
7
8 improve the LVEF (MD=4.18%, 95% CI: 0.36-7.99, P =0.03) among patients with
9
10 HF. In addition, a more pronounced effect is achieved using high-dose vitamin D and
11
12 on patients with a reduced ejection fraction.
13
14
15

16
17
18 Most new treatment methods for chronic HF are expensive and require advanced
19
20 technologies [33]; in addition, most of these treatment methods have not passed strict
21
22 phase III clinical trials. For patients with HF, vitamin D is not only cheap but also safe,
23
24 and these patients may obtain more benefits from vitamin D therapy [34]. Vitamin D
25
26 toxicity is based not only on the dosing but also on circulating 25OHD levels. The
27
28 Institute of Medicine [35] has set the dosage for vitamin D at 4,000IU daily for
29
30 healthy adults, and the Endocrine Society [36] has set a dosage of 10,000IU daily for
31
32 patients who are at risk of having circulating 25OHD levels <50 nmol/L. The Institute
33
34 of Medicine [35] considers circulating 25OHD levels below 30 nmol/L as deficient,
35
36 levels between 30 and 49.99 nmol/L as inadequate, levels between 50 and 125 nmol/L
37
38 as adequate, and levels above 125 nmol/L as potentially harmful. In HF, cardiac
39
40 contraction and diastole are affected due to overload of Ca²⁺ ions in myocardial cells.
41
42 Lack of vitamin D may intervene with the functions of Ca²⁺ in myocardial cells, thus
43
44 resulting in cardiomyocyte hypertrophy and intra-organizational inflammatory
45
46 reaction and fibrosis [37,38]. Low vitamin D levels can activate the renin-angiotensin
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 system [39], give rise to inflammatory reactions [40], and result in endothelial
4
5
6 dysfunction [41]. The effects of vitamin D on the CV system are additionally
7
8 mediated through elevated parathyroid hormone (PTH) levels, which are associated
9
10 with the development of left ventricular (LV) hypertrophy [42]. Although there is
11
12 much evidence showing that a lack of vitamin D could result in poor prognosis among
13
14 patients with HF, different studies have reported controversial conclusions regarding
15
16 whether supplementation of vitamin D could benefit patients with HF.
17
18
19
20
21
22
23

24 In recent years, there some relatively small RCTs have studied the influence of
25
26 vitamin D on patients with HF. In the 2014 World Heart Failure Conference, Louise
27
28 et al [43] reported an RCT that performed a 6-month study on 32 patients with HF,
29
30 and the result showed that supplementation of vitamin D did not improve the LVEF or
31
32 pro-BNP level. A recent meta-analysis [44] also reported that vitamin D
33
34 supplementation could not improve the LVEF (WMD: 4.11%, 95% CI: -0.91 to 9.12,
35
36 P =0.11) and 6-minute walk distance (6MWD) (WMD: 8.90 m, 95% CI: -48.47 to
37
38 66.26, P =0.76) in the treatment of chronic HF. In contrast, this study included three
39
40 other studies, two of which showed a positive effect from vitamin D supplementation.
41
42
43
44
45
46
47 The present studies have not shown that vitamin D supplementation can improve the
48
49 6MWD among patients [26,30,45,46]; thus, our meta-analysis did not evaluate this
50
51 parameter. There are probably many factors that affect exercise tolerance, such as
52
53 physical condition, obesity, habits, and environment, and these confounding factors
54
55
56
57
58
59
60

1
2
3
4 may obscure the weak force from the remodelled ventricle. However, other studies
5
6 have drawn opposite conclusions. In 2015, Lowry et al [47] reported in the European
7
8 Society of Cardiology a 12-month RCT, and the result showed that for patients with
9
10 HF, supplementation of vitamin D could improve ventricular remodelling (LVEDD
11
12 -4.46 mm; $P = 0.047$); in addition, the LVEF showed an increasing trend. A non-RCT
13
14 [48] also showed that supplementation of vitamin D could remarkably increase the
15
16 LVEF value compared to baseline. Elidrissy et al [49] evaluated 61 cases of children
17
18 with cardiomyopathy; they concluded, based on the available evidence, that the most
19
20 likely cause of cardiomyopathy is hypocalcaemia and suggested maternal
21
22 supplementation of vitamin D during pregnancy and lactation with up to 2,000 units
23
24 of vitamin D and 400 units for their infants for prevention, which was also similar to
25
26 the results reported by Shedeed [29].
27
28
29
30
31
32
33
34
35
36

37 Since there are disputes among different study results, we conducted a meta-analysis
38
39 of relevant RCT studies to further clarify the influence of vitamin D supplementation
40
41 on ventricular remodelling in patients with HF. Results of this study show that
42
43 supplementation of vitamin D inhibit myocardial remodelling and improve cardiac
44
45 function in patients with HF.
46
47
48
49
50

51
52 Different studies have different results and conclusions, which may be attributed to
53
54 the different recommended dosages of vitamin D; since there is no standard
55
56

1
2
3 recommended dosage of vitamin D at present, there are differences in the
4
5 recommended dosage of vitamin D in different trials, which may affect the study
6
7 results. However, there has not been a report related to adverse effects from the
8
9 dosage of vitamin D. Meanwhile, the study results are related to the selected group;
10
11 for example, the study results of Schleithoff et al [28] showed that there were no
12
13 remarkable changes in the LVEF and LVEDD, and the participants included in this
14
15 study were predominantly those with NYHA level 3-4 and a high degree of HF, and
16
17 there was a high rate of lost to follow-up visit (37%).
18
19
20
21
22
23
24
25

26 The data on changes in the LVEDD showed high levels of heterogeneity among
27
28 studies. Shedeed [29] studied the cause of heterogeneity according to subgroup. There
29
30 was a difference in the metabolism of vitamin D and cardiac recovery capacity
31
32 between new-borns and adults, which might be the cause of heterogeneity.
33
34
35
36
37
38

39 Although all trials included in this study are RCTs, there are still many limitations in
40
41 this study: 1) because the current studies found that vitamin D has a weak and
42
43 uncertain effect on ventricular remodelling and cardiac function in patients with HF
44
45 and cannot improve exercise tolerance or reduce cardiac mortality, additional
46
47 large-scale clinical studies are needed. Future research needs to focus on whether
48
49 different vitamin D dosages would be superior; in addition, different selection criteria
50
51 need to be defined (for example, ejection fraction, vitamin D threshold, PTH threshold,
52
53
54
55
56
57
58
59
60

1
2
3 etc.) and additional echocardiographic parameters, the 6MWD and cardiovascular
4
5 mortality need to be evaluated; 2) this study exhibits heterogeneity, and age
6
7 stratification and whether there is reduced ejection fraction may be sources of clinical
8
9 heterogeneity according to the subgroup analysis; 3) different recommended dosages
10
11 of vitamin D are reported in different trials, which may affect study results; therefore,
12
13 additional trials are required to explore the relationship between vitamin D dosage and
14
15 effect; 4) the conclusions need to be interpreted with caution, as the extent of detected
16
17 improvement in the remodelling parameters is close to the range of the inter- or
18
19 intra-observer variability of the echocardiographic method itself. The baseline vitamin
20
21 D level of patients and the follow-up duration may affect the study results, and except
22
23 for Dalbeni et al [27], whom have mentioned that no change in therapy was made
24
25 during follow-up, other studies have not reported adjustments in HF medication.
26
27 Therefore, whether the weak improvement in the remodelling parameters from
28
29 vitamin D are attributed to other HF drugs is unclear.
30
31
32
33
34
35
36
37
38
39
40
41

42 In conclusion, this study shows that supplementation of vitamin D inhibit myocardial
43
44 remodelling in patients with HF and improve their cardiac function. Vitamin D may
45
46 be utilized as adjunctive HF medication for HF patients with an underlying lack of or
47
48 insufficiency in vitamin D. This result is encouraging and of great clinical interest but
49
50 still far from practical implications. The main implication is to encourage further
51
52 research.
53
54
55
56
57
58
59
60

1
2
3
4
5
6 **Figure legends**
7

8 **Figure 1** Flow diagram of study selection.
9

10 **Figure 2** Quality assessment.
11

12 **Figure 3** Forest plot showing the effect of Vitamin D on LVEDD.
13

14 **Figure 4** Forest plot showing the effect of Vitamin D on LVEF.
15

16 **Figure 5** Subgroup analysis of effect of Vitamin D on LVEDD according to patients'
17 age.
18

19 **Figure 6** Subgroup analysis of effect of Vitamin D on LVEDD according to dose of
20 Vitamin D.
21

22 **Figure 7** Subgroup analysis of effect of Vitamin D on LVEDD according to patients
23 with or without reduced ejection fraction.
24

25 **Figure 8** Subgroup analysis of effect of Vitamin D on LVEF according to patients
26 with or without reduced ejection fraction.
27

28 **Figure 9** Funnel plots for the effect of Vitamin D on LVEDD
29

30 **Figure 10** Funnel plots for the effect of Vitamin D on LVEF.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Study characteristics.

Author	Design	Blinding	Vitamin D Dose	Follow-up Duration	Study population	Primary Outcome
Turrini et al, 2017	Prospective RCT	Double-blind	300.000 IU at Baseline 50.000IU/mo	6 mo	Chronic HF, 25(OH)D <20 ng/mL, 60 y<Age,	6MWD, echocardiography Parameters, hormonal
Witte et al, 2016	Prospective RCT	Double-blind	4000IU/d	12 mo	Chronic HF, NYHA class II–III, LVEF<45%, 25(OH)D <20 ng/mL	6MWD, echocardiography parameters
Qu et al, 2015	Prospective RCT	Single-blind	1000 IU/d	3 mo	NYHA class III–IV	echocardiography parameters, BNP, 25(OH)D
Dalbeni et	Prospective	Double-blind	4000IU/d	25 wk	Chronic HF, LVEF<55%,	Echocardiographic parameters,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

al, 2014	RCT					NYHA class>II,	NYHA class,
						25(OH)D <30ng/mL, Age >40 y,	NT-proBNP
Boxer er	Prospective	Double-blind	50000IU/wk	6mo		Age ≥50 y, NYHA class II–IV,	Echocardiographic parameters,
al,2014	RCT					25(OH)D <37.5 ng/mL	serum analysis, urine analysis
Shedeed,	Prospective					Congestive HF, LVEF<40%,	Echocardiographic parameters
2012	RCT	Double-blind	1000 IU/d	12 wk		LV>2 SD for age and sex	
Schleithoff	Prospective	Double-blind	2000 IU/d	9 mo		Chronic HF,	Survival rates, NT-proBNP,
et al, 2006	RCT					NYHA class II–IV	Pro-and anti-inflammatory cytokines,
							Echocardiographic parameters,

†25(OH)D; ‡6MWD; §HF; **IU; ††LV; ‡‡LVEF; §§NT-proBNP; ***NYHA;

† 25-hydroxyvitamin D
‡ 6-minute walk distance
§ heart failure

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

For peer review only

Table 2 Study population characteristics.

Intervention Number	Age	Male	LVEF (%)	NYHA	NYHA	NYHA	LVEDD	25(OH)D	Ischemic Hypertension	Diabetes (%)
---------------------	-----	------	----------	------	------	------	-------	---------	-----------------------	--------------

** international units
 †† left ventricular
 ‡‡ left ventricular ejection fraction
 § § N-terminal pro-B-type natriuretic peptide
 *** New York Heart Association

Author	(n)	(years)	(%)		Class	Class	Class	(mm)	(ng/mL)	Cause	(%)		
					II(%)	III(%)	IV(%)			(%)			
Turrini et al, 2017	Vitamin D	17	77±7	35.3	54.7±13.8	64.7	35.3	0	51±1.58	9.4±5.2	41.2	64.7	35.3
	Placebo	16	79±7	43.8	49.2±19.1	68.7	21.3	0	54±3.48	9.6±7.3	43.7	43.7	18.7
Witte et al, 2016	Vitamin D	80	68.5±12.45	83.8	25.6±10.80	92.5	7.5	0	57.6±8.62	38.2±24.81	55.0	NR	21.3
	Placebo	83	69.0±13.78	74.7	26.5±10.62	85.5	14.5	0	58.0±6.49	36.4±20.24	60.2	NR	24.1
Qu et al, 2015	Vitamin D	22	70±7	59.3	34.9±3.8	NR	NR	NR	NR	NR	NR	66.7	81.5
	Blank	17	69±8	51.8	34.6±3.9	NR	NR	NR	NR	NR	NR	63.0	85.2
Dalbeni et al, 2014	Vitamin D	13	71.2±6.22	84.6	39.08±8.00	58.8*	50.0**		53.9±6.81	16.2±6.59	76.9	100	NR
	Placebo	10	73.4±13.78	60.0	43.6±7.63	41.2*	50.0**		50.6±7.04	16.0±6.15	90	100	NR
Boxer et al, 2014	Vitamin D	19	65.8±10.6	48.4	39.2±13.2	55.0	73.0	0	NR	19.1±9.3	25.8	83.0	51.6
	Placebo	15	66.0±10.4	54.5	36.1±14.5	45.0	27.0	0	NR	17.8±9.0	30.3	84.8	42.4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Shedeed,	Vitamin D	42	0.86±1.3	64.29	36.4±2.26	NR	NR	NR	32.81±4.6	13.4±2.21	NR	NR	NR
2012	Placebo	38	0.93±1.0	57.89	37.2±2.62	NR	NR	NR	30.7±5.2	14.0±2.46	NR	NR	NR
	Vitamin D+						NR	NR			47	38	20
Schleithoff	Calcium	42	57±7.41	85.25	32.5±8.67	NR			69.0±8.89	14.4±7.85			
et al, 2006	Placebo+						NR	NR			40	32	23
	Calcium	51	54±8.89	80.65	33.0±7.56	NR			69.0±9.26	15.3±7.48			

†††NR

Review only

††† Not reported
 *I and II
 ** III and IV

Contributor ship statement

Jin-Dong Zhao: Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND Drafting the work or revising it critically for important intellectual content; AND Final approval of the version to be published; AND Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Jing-Jing Jia: participated in writing

Ping-Shuan Dong * : served as scientific advisors

Di Zhao: participated in technical editing of the manuscript

Xu-Ming Yang: critically reviewed the study proposal

Dao-Lin Li: collected data

Hui-Feng Zhang: collected data

Disclosure of conflict of interest

None.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Data sharing statement

The authors declare that they willing to share their data directly.

References

1. Mengchao Jin, Siqi Wei, Rongrong Gao, et al. Predictors of Long-Term Mortality in Patients With Acute Heart Failure. *Int Heart J* 2017; 58: 409-15.
2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail* 2013; 6 : 606–19.
3. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007; 93: 1137–46.
4. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. *JAMA* 2004; 292: 344-50.
5. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2012; 14: 803-69
6. Sun Q, Shi L, Rimm EB, et al. Vitamin D intake and risk of cardiovascular disease in US men and women. *Am J Clin Nutr* 2011; 94: 534-42

- 1
2
3
4 7. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. *Curr*
5
6 *Opin Nephrol Hypertens* 2012; 21: 492–9.
- 7
8
9 8. Karakas M, Thorand B, Zierer A, et al. Low levels of serum 25-hydroxyvitamin
10
11 D are associated with increased risk of myocardial infarction, especially in
12
13 women: results from the MONICA/KORA Augsburg case-cohort study. *J Clin*
14
15 *Endocrinol Metab* 2013; 98: 272–80.
- 16
17
18 9. Sun Q, Pan A, Hu FB, et al. 25-Hydroxyvitamin D levels and the risk of stroke: a
19
20 prospective study and meta-analysis. *Stroke* 2012; 43: 1470–7.
- 21
22
23 10. Desai CK, Huang J, Lokhandwala A, et al. The role of vitamin supplementation
24
25 in the prevention of cardiovascular disease events. *Clin Cardiol* 2014; 37: 576–
26
27 81
- 28
29
30 11. Schierbeck LL, Jensen TS, Bang U, et al. Parathyroid hormone and vitamin
31
32 D—markers for cardiovascular and all cause mortality in heart failure. *Eur J*
33
34 *Heart Fail* 2011; 13: 626–32.
- 35
36
37 12. Liu L, Chen Chen M, Hankins SR, et al. Serum 25-hydroxyvitamin D
38
39 concentration and mortality from heart failure and cardiovascular disease, and
40
41 premature mortality from all-cause in United States adults. *Am J Cardiol* 2012;
42
43 110: 834–9.
- 44
45
46 13. Ford JA, MacLennan GS, Avenell A, et al. Cardiovascular disease and vitamin D
47
48 supplementation: trial analysis, systematic review, and meta-analysis. *Am J Clin*
49
50 *Nutr* 2014; 100: 746–55.
- 51
52
53
54
55
56

- 1
2
3
4 14. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk
5
6 of cardiovascular disease : a meta-analysis of prospective studies. *Circ*
7
8 *Cardiovasc Qual Outcomes* 2012; 5: 819–29.
9
- 10
11 15. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment and
12
13 prevention of vitamin D deficiency: an Endocrine Society clinical practice guide.
14
15 *J Clin Endocrinol Metab* 2011; 96: 1911-30.
16
- 17
18 16. Gotsman I, Shauer A, Zwas DR, et al. Vitamin D deficiency is a predictor of
19
20 reduced survival in patients with heart failure; vitamin D supplementation
21
22 improves outcome. *Eur J Heart Fail* 2012; 14: 357–66
23
- 24
25 17. Pourdjabbar A, Dwivedi G, Haddad H. The role of vitamin D in chronic heart
26
27 failure. *Curr Opin Cardiol.* 2013; 28: 216–22.
28
- 29
30 18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3)
31
32 is a negative endocrine regulator of the renin-angiotensin system. *J Clin Invest*
33
34 2002; 110: 229e38.
35
- 36
37 19. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, et al.
38
39 Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin
40
41 D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular
42
43 Health (LURIC) Study. *Clin Chim Acta* 2010; 411: 1354e60.
44
45
- 46
47 20. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and
48
49 regulation of the renin-angiotensin system in humans. *Hypertension* 2010; 55:
50
51 1283e8.
52
53
54
55
56

- 1
2
3
4 21. Weber KT, Weglicki WB, Simpson RU. Macro- and micronutrient
5
6 dyshomeostasis in the adverse structural remodeling of myocardium. *Cardiovasc*
7
8 *Res* 2009; 81: 500e8.
9
- 10
11 22. Agarwal M, Phan A, Willix Jr R, Barber M, Schwarz ER. Is vitamin D
12
13 deficiency associated with heart failure? A review of current evidence. *J*
14
15 *Cardiovasc Pharmacol Ther.* 2011; 16: 354e63.
16
17
- 18
19 23. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of*
20
21 *Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,*
22
23 2011. Available at: www.cochrane-hand-book.org.
24
25
- 26
27 24. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in
28
29 meta-analyses. *BMJ* 2003; 327: 557-60.
30
31
- 32
33 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat*
34
35 *Med* 2002; 21: 1539–58.
36
37
- 38
39 26. Turrini F, Scarlini S, Giovanardi P, et al.
40
41 Effects of cholecalciferol supplementation in patients with stable heart failure an
42
43 d low vitamin D levels (ECSPLOIT-D). A double-blind, randomized, placebo-con
44
45 trolled pilot study. *Minerva Cardioangiol* 2017 DOI:
46
47 10.23736/S0026-4725.17.04340-7
48
- 49
50 27. Dalbeni A, Scaturro G, Degan M, et al. Effects of six months of vitamin D
51
52 supplementation in patients with heart failure: a randomized double-blind
53
54 controlled trial. *Nutr Metab Cardiovasc Dis* 2014; 24: 861–8.
55
56
57
58
59
60

- 1
2
3
4 28. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation
5
6 improves cytokine profiles in patients with congestive heart failure: a
7
8 double-blind, randomized, placebocontrolled trial. *Am J Clin Nutr* 2006; 83:
9
10 754–9.
11
- 12
13 29. Shedeed SA. Vitamin D supplementation in infants with chronic congestive heart
14
15 failure. *Pediatr Cardiol* 2012; 33: 713–9.
16
- 17
18 30. Witte KK, Byrom R, Gierula J, et al. Effects of vitamin D on cardiac function in
19
20 patients with chronic HF: the VINDICATE study. *J Am Coll Cardiol* 2016; 67:
21
22 2593-603.
23
- 24
25 31. Qu Jun, Wang Zhen, Song hong-bo, et al. The Clinical Effect of Vitamin D 3
26
27 Supplementation on Cardiac Function in Patients with Ischemic Heart Failure.
28
29 *Chinese and Foreign Medical Research*, 2015, 13: 3-5.
30
31
- 32
33 32. Boxer RS, Hoit BD, Schmotzer BJ, et al. The effect of vitamin D on aldosterone
34
35 and health status in patients with heart failure. *J Card Fail* 2014; 20: 334–42
36
37
- 38
39 33. Rie Amai, Teruhiko Imamura, Yasuo Nakahara, et al. Reversible Motor
40
41 Paralysis and Early Cardiac Rehabilitation in Patients With Advanced Heart
42
43 Failure Receiving Left Ventricular Assist Device Therapy. *Int Heart J* 2016; 57:
44
45 766-8
46
47
- 48
49 34. Witte KK, Byrom R. Micronutrients for chronic heart failure: end of the road or
50
51 path to enlightenment? *J Am Coll Cardio HF* 2014; 2: 318–20.
52
53
54
55
56
57

- 1
2
3 35. Institute of Medicine. Dietary Reference Intakes: Calcium and Vitamin D.
4
5
6 Washington, DC: National Academies Press; 2011.
7
- 8
9 36. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and
10
11 prevention of vitamin D deficiency: an Endocrine Society clinical practice
12
13 guideline. *J Clin Endocrinol Metab* 2011; 96: 1911-30.
14
15
- 16 37. Weisshaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular
17
18 function II direct and indirect effects. *Am J Physiol* 1987; 253: E675-83
19
20
- 21 38. Chen S, Law CS, Grigsby CL, et al. Cardiomyocyte-specific deletion of the
22
23 vitamin D receptor gene results in cardiac hypertrophy. *Circulation* 2011; 124:
24
25 1838-47.
26
27
- 28 39. Vaidya A, Williams JS. The relationship between vitamin D and the renin
29
30 angiotensin system in the pathophysiology of hypertension, kidney disease, and
31
32 diabetes. *Metabolism* 2012; 61: 450-8.
33
34
35
- 36 40. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits
37
38 monocyte/macrophage proinflammatory cytokine production by targeting MAPK
39
40 phosphatase-1. *J Immunol* 2012; 188: 2127-35.
41
42
43
- 44 41. Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial
45
46 function and dysfunction. *Arch Med Sci* 2012; 8: 4-5.
47
48
- 49 42. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left
50
51 ventricular hypertrophy. *Eur Heart J* 2003; 24: 2054e60.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 43. LLLouise Schierbeck, J L Madsen, U C Bang, et al. The effect of vitamin D
5
6 supplementation in vitamin D deficient men with heart failure. A randomized
7
8 controlled trial.:P1686. European journal of heart failure 2014, 16, 335 Online
9
10
11 Publication Date: 2014
12
13
14 44. Jiang WL, Gu HB, Zhang YF, et al. Vitamin D Supplementation in the
15
16 Treatment of Chronic Heart Failure: A Meta-analysis of Randomized Controlled
17
18 Trials. Clin Cardiol 2016; 39: 56-61.
19
20
21 45. Boxer RS, Kenny AM, Schmotzer BJ, et al. A randomized controlled trial of
22
23 high dose vitamin D3 in patients with heart failure. JACC Heart Fail 2013; 1:
24
25 84-90.
26
27
28
29 46. Witham MD, Crighton LJ, Gillespie ND, et al. The effects of vitamin D
30
31 supplementation on physical function and quality of life in older patients with
32
33 heart failure: a randomized controlled trial. Circ Heart Fail 2010; 3: 195–201.
34
35
36
37 47. Lowry J , Gierula J , Byrom R, et al. Vitamin D supplementation improves the
38
39 size and function of the left ventricle in patients with heart failure . European
40
41 heart journal 2015, 36, 665 Online Publication Date: 2016
42
43
44 48. Zia AA, Komolafe BO, Moten M, et al. Supplemental vitamin D and calcium in
45
46 the management of African Americans with heart failure having hypovitaminosis
47
48 D. Am J Med Sci 2011;341:113-118.
49
50
51
52 49. Elidrissy AT, MunawarahM, Alharbi KM. Hypocalcemic rachitic
53
54 cardiomyopathy in infants. J Saudi Heart Assoc 2013; 25: 25-33.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Flow diagram of study selection.

176x155mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)
Boxer 2014	+	+	?	+	+	+
Dalbeni 2014	+	?	+	+	+	+
Qu 2015	?	?	?	+	+	+
Schleithoff 2006	+	?	?	+	+	+
Shedeed 2012	+	+	+	+	+	+
Turrini 2017	?	?	+	+	+	+
Witte 2016	?	?	+	+	+	+

Figure 2 Quality assessment.

422x794mm (300 x 300 DPI)




Figure 3 Forest plot showing the effect of Vitamin D on LVEDD.

92x20mm (300 x 300 DPI)




Figure 4 Forest plot showing the effect of Vitamin D on LVEF.

92x24mm (300 x 300 DPI)




Figure 5 Subgroup analysis of effect of Vitamin D on LVEDD according to patients' age.

123x48mm (300 x 300 DPI)




Figure 6 Subgroup analysis of effect of Vitamin D on LVEDD according to dose of Vitamin D.

99x38mm (300 x 300 DPI)




Figure 7 Subgroup analysis of effect of Vitamin D on LVEDD according to patients with or without reduced ejection fraction.

118x46mm (300 x 300 DPI)




Figure 8 Subgroup analysis of effect of Vitamin D on LVEF according to patients with or without reduced ejection fraction.

129x55mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 9 Funnel plots for the effect of Vitamin D on LVEDD

105x70mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 10 Funnel plots for the effect of Vitamin D on LVEF.

105x70mm (300 x 300 DPI)

view only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	5
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	10
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	10
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	11
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	24

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>